1-1	0-12	Disturbances	_	_
1-2	13-19	across	_	_
1-3	20-25	whole	_	_
1-4	26-31	brain	_	_
1-5	32-40	networks	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-6	41-47	during	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-7	48-54	reward	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
1-8	55-67	anticipation	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-9	68-70	in	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-10	71-73	an	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-11	74-83	abstinent	_	_
1-12	84-93	addiction	_	_
1-13	94-104	population	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-14	105-114	Graphical	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-15	115-123	abstract	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-16	124-131	Network	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-17	132-137	based	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-18	138-148	statistics	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-19	149-150	(	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-20	150-153	NBS	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-21	153-154	)	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-22	155-163	analyses	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-23	164-172	detected	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-24	173-174	a	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-25	175-180	graph	_	_
1-26	181-192	sub-network	_	_
1-27	193-203	comprising	_	_
1-28	204-207	153	_	_
1-29	208-213	edges	_	_
1-30	214-221	between	_	_
1-31	222-224	59	_	_
1-32	225-230	nodes	_	_
1-33	231-233	of	_	_
1-34	234-237	the	_	_
1-35	238-248	connectome	_	_
1-36	249-254	where	_	_
1-37	255-258	the	_	_
1-38	259-262	ADD	_	_
1-39	263-268	group	_	_
1-40	269-281	demonstrated	_	_
1-41	282-295	significantly	_	_
1-42	296-300	less	_	_
1-43	301-313	connectivity	_	_
1-44	314-322	compared	_	_
1-45	323-327	with	_	_
1-46	328-331	the	_	_
1-47	332-335	CON	_	_
1-48	336-341	group	_	_
1-49	341-342	.	_	_

2-1	343-348	These	_	_
2-2	349-360	differences	_	_
2-3	361-363	in	_	_
2-4	364-376	connectivity	_	_
2-5	377-381	were	_	_
2-6	382-388	mostly	_	_
2-7	389-406	intra-hemispheric	_	_
2-8	407-408	(	_	_
2-9	408-411	55%	_	_
2-10	411-412	)	_	_
2-11	412-413	,	_	_
2-12	414-417	the	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
2-13	418-426	majority	_	_
2-14	427-428	(	_	_
2-15	428-431	38%	_	_
2-16	431-432	)	_	_
2-17	433-438	being	_	_
2-18	439-441	in	_	_
2-19	442-445	the	_	_
2-20	446-451	right	_	_
2-21	452-462	hemisphere	_	_
2-22	462-463	.	_	_

3-1	464-467	The	_	_
3-2	468-478	anatomical	_	_
3-3	479-491	distribution	_	_
3-4	492-494	of	_	_
3-5	495-500	these	_	_
3-6	501-513	connectivity	_	_
3-7	514-525	differences	_	_
3-8	526-533	between	_	_
3-9	534-537	the	_	_
3-10	538-541	two	_	_
3-11	542-548	groups	_	_
3-12	549-557	involved	_	_
3-13	558-565	frontal	_	_
3-14	566-567	(	_	_
3-15	567-573	insula	_	_
3-16	573-574	,	_	_
3-17	575-583	inferior	_	_
3-18	584-591	frontal	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-19	592-597	gyrus	_	_
3-20	597-598	,	_	_
3-21	599-612	orbitofrontal	_	_
3-22	613-619	cortex	_	_
3-23	619-620	)	_	_
3-24	620-621	,	_	_
3-25	622-639	limbic-associated	_	_
3-26	640-641	(	_	_
3-27	641-649	anterior	_	_
3-28	650-659	cingulate	_	_
3-29	660-665	gyrus	_	_
3-30	665-666	,	_	_
3-31	667-675	thalamus	_	_
3-32	675-676	)	_	_
3-33	676-677	,	_	_
3-34	678-681	and	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
3-35	682-690	striatal	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
3-36	691-692	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
3-37	692-701	accumbens	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
3-38	701-702	,	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
3-39	703-710	caudate	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-40	710-711	,	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-41	712-720	pallidum	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-42	720-721	)	_	_
3-43	722-729	regions	_	_
3-44	729-730	.	_	_

4-1	731-734	The	_	_
4-2	735-747	connectivity	_	_
4-3	748-759	differences	_	_
4-4	760-768	reported	_	_
4-5	769-771	in	_	_
4-6	772-776	this	_	_
4-7	777-780	ADD	_	_
4-8	781-787	sample	_	_
4-9	788-796	indicate	_	_
4-10	797-808	alterations	_	_
4-11	809-816	between	_	_
4-12	817-826	cognitive	_	_
4-13	826-827	,	_	_
4-14	828-836	striatal	_	_
4-15	837-840	and	_	_
4-16	841-858	limbic-associated	_	_
4-17	859-866	regions	_	_
4-18	867-873	during	_	_
4-19	874-880	reward	_	_
4-20	881-893	anticipation	_	_
4-21	894-898	that	_	_
4-22	899-906	persist	_	_
4-23	907-911	into	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
4-24	912-920	extended	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-25	921-931	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-26	931-932	.	_	_

5-1	933-943	Highlights	_	_
5-2	944-954	Analytical	_	_
5-3	955-962	methods	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-4	963-966	can	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-5	967-974	capture	_	_
5-6	975-978	key	_	_
5-7	979-987	features	_	_
5-8	988-990	of	_	_
5-9	991-996	whole	_	_
5-10	997-1002	brain	_	_
5-11	1003-1011	networks	_	_
5-12	1012-1014	in	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
5-13	1015-1024	addiction	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
5-14	1024-1025	.	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_

6-1	1026-1028	We	_	_
6-2	1029-1037	compared	_	_
6-3	1038-1044	reward	_	_
6-4	1045-1052	network	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-5	1053-1065	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-6	1066-1068	in	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-7	1069-1078	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-8	1079-1080	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-9	1080-1083	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-10	1083-1084	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-11	1085-1088	and	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-12	1089-1096	control	_	_
6-13	1097-1098	(	_	_
6-14	1098-1101	CON	_	_
6-15	1101-1102	)	_	_
6-16	1103-1109	groups	_	_
6-17	1109-1110	.	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus

7-1	1111-1114	The	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
7-2	1115-1118	ADD	_	_
7-3	1119-1124	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
7-4	1125-1131	showed	_	_
7-5	1132-1143	disruptions	_	_
7-6	1144-1146	in	_	_
7-7	1147-1153	global	_	_
7-8	1154-1161	network	_	_
7-9	1162-1174	connectivity	_	_
7-10	1174-1175	.	_	_

8-1	1176-1182	Global	_	_
8-2	1183-1190	network	_	_
8-3	1191-1199	measures	_	_
8-4	1200-1203	may	_	_
8-5	1204-1206	be	_	_
8-6	1207-1211	more	_	_
8-7	1212-1221	sensitive	_	_
8-8	1222-1226	than	_	_
8-9	1227-1238	traditional	_	_
8-10	1239-1249	voxel-wise	_	_
8-11	1250-1258	analyses	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
8-12	1258-1259	.	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_

9-1	1260-1263	The	_	_
9-2	1264-1273	prevalent	_	_
9-3	1274-1281	spatial	_	_
9-4	1282-1294	distribution	_	_
9-5	1295-1297	of	_	_
9-6	1298-1311	abnormalities	_	_
9-7	1312-1320	reported	_	_
9-8	1321-1323	in	_	_
9-9	1324-1333	cognitive	_	_
9-10	1334-1338	fMRI	_	_
9-11	1339-1346	studies	_	_
9-12	1347-1349	in	_	_
9-13	1350-1359	addiction	_	_
9-14	1360-1368	suggests	_	_
9-15	1369-1374	there	_	_
9-16	1375-1378	are	_	_
9-17	1379-1388	extensive	_	_
9-18	1389-1400	disruptions	_	_
9-19	1401-1407	across	_	_
9-20	1408-1413	whole	_	_
9-21	1414-1419	brain	_	_
9-22	1420-1428	networks	_	_
9-23	1428-1429	.	_	_

10-1	1430-1437	Studies	_	_
10-2	1438-1443	using	_	_
10-3	1444-1451	resting	_	_
10-4	1452-1457	state	_	_
10-5	1458-1462	have	_	_
10-6	1463-1471	reported	_	_
10-7	1472-1483	disruptions	_	_
10-8	1484-1486	in	_	_
10-9	1487-1494	network	_	_
10-10	1495-1507	connectivity	_	_
10-11	1508-1510	in	_	_
10-12	1511-1520	addiction	_	_
10-13	1520-1521	,	_	_
10-14	1522-1525	but	_	_
10-15	1526-1531	these	_	_
10-16	1532-1539	studies	_	_
10-17	1540-1544	have	_	_
10-18	1545-1548	not	_	_
10-19	1549-1557	revealed	_	_
10-20	1558-1573	characteristics	_	_
10-21	1574-1576	of	_	_
10-22	1577-1584	network	_	_
10-23	1585-1596	functioning	_	_
10-24	1597-1603	during	_	_
10-25	1604-1612	critical	_	_
10-26	1613-1626	psychological	_	_
10-27	1627-1636	processes	_	_
10-28	1637-1641	that	_	_
10-29	1642-1645	are	_	_
10-30	1646-1655	disrupted	_	_
10-31	1656-1658	in	_	_
10-32	1659-1668	addiction	_	_
10-33	1669-1680	populations	_	_
10-34	1680-1681	.	_	_

11-1	1682-1690	Analytic	_	_
11-2	1691-1698	methods	_	_
11-3	1699-1703	that	_	_
11-4	1704-1707	can	_	_
11-5	1708-1715	capture	_	_
11-6	1716-1719	key	_	_
11-7	1720-1728	features	_	_
11-8	1729-1731	of	_	_
11-9	1732-1737	whole	_	_
11-10	1738-1743	brain	_	_
11-11	1744-1752	networks	_	_
11-12	1753-1759	during	_	_
11-13	1760-1773	psychological	_	_
11-14	1774-1783	processes	_	_
11-15	1784-1787	may	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
11-16	1788-1790	be	_	_
11-17	1791-1795	more	_	_
11-18	1796-1805	sensitive	_	_
11-19	1806-1808	in	_	_
11-20	1809-1818	revealing	_	_
11-21	1819-1829	additional	_	_
11-22	1830-1833	and	_	_
11-23	1834-1844	widespread	_	_
11-24	1845-1851	neural	_	_
11-25	1852-1864	disturbances	_	_
11-26	1865-1867	in	_	_
11-27	1868-1877	addiction	_	_
11-28	1877-1878	,	_	_
11-29	1879-1883	that	_	_
11-30	1884-1887	are	_	_
11-31	1888-1891	the	_	_
11-32	1892-1902	provisions	_	_
11-33	1903-1906	for	_	_
11-34	1907-1914	relapse	_	_
11-35	1915-1919	risk	_	_
11-36	1919-1920	,	_	_
11-37	1921-1924	and	_	_
11-38	1925-1932	targets	_	_
11-39	1933-1936	for	_	_
11-40	1937-1947	medication	_	_
11-41	1948-1959	development	_	_
11-42	1959-1960	.	_	_

12-1	1961-1964	The	_	_
12-2	1965-1972	current	_	_
12-3	1973-1978	study	_	_
12-4	1979-1987	compared	_	_
12-5	1988-1989	a	_	_
12-6	1990-1999	substance	_	_
12-7	2000-2009	addiction	_	_
12-8	2010-2011	(	_	_
12-9	2011-2014	ADD	_	_
12-10	2014-2015	;	_	_
12-11	2016-2017	n	_	_
12-12	2017-2018	 	_	_
12-13	2018-2019	=	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-14	2019-2020	 	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-15	2020-2022	83	_	_
12-16	2022-2023	)	_	_
12-17	2024-2029	group	_	_
12-18	2030-2032	in	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
12-19	2033-2041	extended	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
12-20	2042-2052	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-21	2053-2057	with	_	_
12-22	2058-2059	a	_	_
12-23	2060-2067	control	_	_
12-24	2068-2069	(	_	_
12-25	2069-2072	CON	_	_
12-26	2072-2073	;	_	_
12-27	2074-2075	n	_	_
12-28	2075-2076	 	_	_
12-29	2076-2077	=	_	_
12-30	2077-2078	 	_	_
12-31	2078-2080	68	_	_
12-32	2080-2081	)	_	_
12-33	2082-2087	group	_	_
12-34	2088-2090	on	_	_
12-35	2091-2101	functional	_	_
12-36	2102-2105	MRI	_	_
12-37	2106-2107	(	_	_
12-38	2107-2117	voxel-wise	_	_
12-39	2118-2128	activation	_	_
12-40	2128-2129	)	_	_
12-41	2130-2133	and	_	_
12-42	2134-2140	global	_	_
12-43	2141-2148	network	_	_
12-44	2149-2150	(	_	_
12-45	2150-2162	connectivity	_	_
12-46	2162-2163	)	_	_
12-47	2164-2172	measures	_	_
12-48	2173-2180	related	_	_
12-49	2181-2183	to	_	_
12-50	2184-2190	reward	_	_
12-51	2191-2203	anticipation	_	_
12-52	2204-2206	on	_	_
12-53	2207-2208	a	_	_
12-54	2209-2217	monetary	_	_
12-55	2218-2227	incentive	_	_
12-56	2228-2233	delay	_	_
12-57	2234-2238	task	_	_
12-58	2238-2239	.	_	_

13-1	2240-2242	In	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-2	2243-2246	the	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-3	2247-2254	absence	_	_
13-4	2255-2257	of	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-5	2258-2263	group	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-6	2264-2275	differences	_	_
13-7	2276-2278	on	_	_
13-8	2279-2282	MID	_	_
13-9	2283-2294	performance	_	_
13-10	2294-2295	,	_	_
13-11	2296-2299	the	_	_
13-12	2300-2303	ADD	_	_
13-13	2304-2309	group	_	_
13-14	2310-2316	showed	_	_
13-15	2317-2324	reduced	_	_
13-16	2325-2335	activation	_	_
13-17	2336-2349	predominantly	_	_
13-18	2350-2356	across	_	_
13-19	2357-2365	temporal	_	_
13-20	2366-2369	and	_	_
13-21	2370-2376	visual	_	_
13-22	2377-2384	regions	_	_
13-23	2384-2385	,	_	_
13-24	2386-2389	but	_	_
13-25	2390-2393	not	_	_
13-26	2394-2400	across	_	_
13-27	2401-2404	the	_	_
13-28	2405-2413	striatum	_	_
13-29	2413-2414	.	_	_

14-1	2415-2418	The	_	_
14-2	2419-2422	ADD	_	_
14-3	2423-2428	group	_	_
14-4	2429-2433	also	_	_
14-5	2434-2440	showed	_	_
14-6	2441-2452	disruptions	_	_
14-7	2453-2455	in	_	_
14-8	2456-2462	global	_	_
14-9	2463-2470	network	_	_
14-10	2471-2483	connectivity	_	_
14-11	2484-2485	(	_	_
14-12	2485-2490	lower	_	_
14-13	2491-2501	clustering	_	_
14-14	2502-2513	coefficient	_	_
14-15	2514-2517	and	_	_
14-16	2518-2524	higher	_	_
14-17	2525-2539	characteristic	_	_
14-18	2540-2544	path	_	_
14-19	2545-2551	length	_	_
14-20	2551-2552	)	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-21	2552-2553	,	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-22	2554-2557	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-23	2558-2571	significantly	_	_
14-24	2572-2576	less	_	_
14-25	2577-2589	connectivity	_	_
14-26	2590-2596	across	_	_
14-27	2597-2598	a	_	_
14-28	2599-2610	sub-network	_	_
14-29	2611-2621	comprising	_	_
14-30	2622-2629	frontal	_	_
14-31	2629-2630	,	_	_
14-32	2631-2639	temporal	_	_
14-33	2639-2640	,	_	_
14-34	2641-2647	limbic	_	_
14-35	2648-2651	and	_	_
14-36	2652-2660	striatal	_	_
14-37	2661-2666	nodes	_	_
14-38	2666-2667	.	_	_

15-1	2668-2673	These	_	_
15-2	2674-2681	results	_	_
15-3	2682-2686	show	_	_
15-4	2687-2691	that	_	_
15-5	2692-2694	an	_	_
15-6	2695-2704	addiction	_	_
15-7	2705-2710	group	_	_
15-8	2711-2713	in	_	_
15-9	2714-2722	extended	_	_
15-10	2723-2733	abstinence	_	_
15-11	2734-2741	exhibit	_	_
15-12	2742-2751	localised	_	_
15-13	2752-2763	disruptions	_	_
15-14	2764-2766	in	_	_
15-15	2767-2772	brain	_	_
15-16	2773-2783	activation	_	_
15-17	2783-2784	,	_	_
15-18	2785-2788	but	_	_
15-19	2789-2793	more	_	_
15-20	2794-2803	extensive	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-21	2804-2816	disturbances	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-22	2817-2819	in	_	_
15-23	2820-2830	functional	_	_
15-24	2831-2843	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
15-25	2844-2850	across	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
15-26	2851-2856	whole	_	_
15-27	2857-2862	brain	_	_
15-28	2863-2871	networks	_	_
15-29	2871-2872	.	_	_

16-1	2873-2875	We	_	_
16-2	2876-2883	propose	_	_
16-3	2884-2888	that	_	_
16-4	2889-2897	measures	_	_
16-5	2898-2900	of	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
16-6	2901-2907	global	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
16-7	2908-2915	network	_	_
16-8	2916-2927	functioning	_	_
16-9	2928-2931	may	_	_
16-10	2932-2934	be	_	_
16-11	2935-2939	more	_	_
16-12	2940-2949	sensitive	_	_
16-13	2950-2952	in	_	_
16-14	2953-2965	highlighting	_	_
16-15	2966-2972	latent	_	_
16-16	2973-2976	and	_	_
16-17	2977-2981	more	_	_
16-18	2982-2992	widespread	_	_
16-19	2993-2999	neural	_	_
16-20	3000-3011	disruptions	_	_
16-21	3012-3018	during	_	_
16-22	3019-3027	critical	_	_
16-23	3028-3041	psychological	_	_
16-24	3042-3051	processes	_	_
16-25	3052-3054	in	_	_
16-26	3055-3064	addiction	_	_
16-27	3065-3068	and	_	_
16-28	3069-3074	other	_	_
16-29	3075-3086	psychiatric	_	_
16-30	3087-3096	disorders	_	_
16-31	3096-3097	.	_	_















31-1	6090-6098	Material	_	_
31-2	6099-6102	and	_	_
31-3	6103-6110	methods	_	_
31-4	6111-6123	Participants	_	_
31-5	6124-6135	Sixty-eight	_	_
31-6	6136-6143	control	_	_
31-7	6144-6145	(	_	_
31-8	6145-6148	CON	_	_
31-9	6148-6149	:	_	_
31-10	6150-6154	mean	_	_
31-11	6155-6158	age	_	_
31-12	6159-6164	39.79	_	_
31-13	6164-6165	 	_	_
31-14	6165-6166	±	_	_
31-15	6166-6167	 	_	_
31-16	6167-6171	1.22	_	_
31-17	6171-6172	;	_	_
31-18	6173-6175	18	_	_
31-19	6176-6183	females	_	_
31-20	6183-6184	,	_	_
31-21	6185-6187	50	_	_
31-22	6188-6193	males	_	_
31-23	6193-6194	)	_	_
31-24	6195-6198	and	_	_
31-25	6199-6201	83	_	_
31-26	6202-6211	addiction	_	_
31-27	6212-6213	(	_	_
31-28	6213-6216	ADD	_	_
31-29	6216-6217	:	_	_
31-30	6218-6222	mean	_	_
31-31	6223-6226	age	_	_
31-32	6227-6232	40.05	_	_
31-33	6232-6233	 	_	_
31-34	6233-6234	±	_	_
31-35	6234-6235	 	_	_
31-36	6235-6239	0.92	_	_
31-37	6239-6240	;	_	_
31-38	6241-6243	16	_	_
31-39	6244-6251	females	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
31-40	6251-6252	,	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
31-41	6253-6255	67	_	_
31-42	6256-6261	males	_	_
31-43	6261-6262	)	_	_
31-44	6263-6275	participants	_	_
31-45	6276-6285	completed	_	_
31-46	6286-6289	the	_	_
31-47	6290-6297	current	_	_
31-48	6298-6303	study	_	_
31-49	6303-6304	.	_	_

32-1	6305-6308	The	_	_
32-2	6309-6316	current	_	_
32-3	6317-6324	dataset	_	_
32-4	6325-6328	was	_	_
32-5	6329-6338	collected	_	_
32-6	6339-6341	as	_	_
32-7	6342-6346	part	_	_
32-8	6347-6349	of	_	_
32-9	6350-6351	a	_	_
32-10	6352-6364	multi-centre	_	_
32-11	6365-6370	study	_	_
32-12	6371-6380	involving	_	_
32-13	6381-6386	three	_	_
32-14	6387-6392	study	_	_
32-15	6393-6398	sites	_	_
32-16	6399-6401	in	_	_
32-17	6402-6405	the	_	_
32-18	6406-6412	United	_	_
32-19	6413-6420	Kingdom	_	_
32-20	6421-6422	(	_	_
32-21	6422-6430	Imperial	_	_
32-22	6431-6438	College	_	_
32-23	6439-6445	London	_	_
32-24	6445-6446	,	_	_
32-25	6447-6457	University	_	_
32-26	6458-6460	of	_	_
32-27	6461-6470	Cambridge	_	_
32-28	6471-6474	and	_	_
32-29	6475-6485	University	_	_
32-30	6486-6488	of	_	_
32-31	6489-6499	Manchester	_	_
32-32	6500-6501	–	_	_
32-33	6502-6507	ICCAM	_	_
32-34	6507-6508	)	_	_
32-35	6508-6509	.	_	_

33-1	6510-6513	For	_	_
33-2	6514-6515	a	_	_
33-3	6516-6520	more	_	_
33-4	6521-6529	detailed	_	_
33-5	6530-6541	description	_	_
33-6	6542-6544	of	_	_
33-7	6545-6548	the	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
33-8	6549-6554	ICCAM	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
33-9	6555-6563	Platform	_	_
33-10	6563-6564	,	_	_
33-11	6565-6568	see	_	_
33-12	6568-6569	)	_	_
33-13	6570-6573	and	_	_
33-14	6573-6574	.	_	_

34-1	6575-6584	Inclusion	_	_
34-2	6585-6593	criteria	_	_
34-3	6594-6598	were	_	_
34-4	6599-6610	individuals	_	_
34-5	6611-6614	who	_	_
34-6	6615-6618	met	_	_
34-7	6619-6625	DSM-IV	_	_
34-8	6626-6634	measures	_	_
34-9	6635-6638	for	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
34-10	6639-6646	current	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
34-11	6647-6649	or	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
34-12	6650-6655	prior	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
34-13	6656-6665	substance	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
34-14	6666-6676	dependence	_	_
34-15	6677-6678	(	_	_
34-16	6678-6681	e.g	_	_
34-17	6681-6682	.	_	_
34-18	6682-6683	,	_	_
34-19	6684-6691	alcohol	_	_
34-20	6691-6692	,	_	_
34-21	6693-6700	cocaine	_	_
34-22	6700-6701	,	_	_
34-23	6702-6709	opiates	_	_
34-24	6709-6710	)	_	_
34-25	6710-6711	.	_	_

35-1	6712-6715	The	_	_
35-2	6716-6719	ADD	_	_
35-3	6720-6725	group	_	_
35-4	6726-6735	consisted	_	_
35-5	6736-6738	of	_	_
35-6	6739-6741	29	_	_
35-7	6742-6743	(	_	_
35-8	6743-6746	35%	_	_
35-9	6746-6747	)	_	_
35-10	6748-6752	pure	_	_
35-11	6753-6770	alcohol-dependent	_	_
35-12	6770-6771	,	_	_
35-13	6772-6774	42	_	_
35-14	6775-6776	(	_	_
35-15	6776-6779	50%	_	_
35-16	6779-6780	)	_	_
35-17	6781-6785	poly	_	_
35-18	6786-6805	substance-dependent	_	_
35-19	6806-6807	(	_	_
35-20	6807-6810	e.g	_	_
35-21	6810-6811	.	_	_
35-22	6811-6812	,	_	_
35-23	6813-6820	alcohol	_	_
35-24	6821-6824	and	_	_
35-25	6825-6832	cocaine	_	_
35-26	6832-6833	,	_	_
35-27	6834-6841	cocaine	_	_
35-28	6842-6845	and	_	_
35-29	6846-6852	opiate	_	_
35-30	6852-6853	)	_	_
35-31	6854-6857	and	_	_
35-32	6858-6860	12	_	_
35-33	6861-6862	(	_	_
35-34	6862-6865	15%	_	_
35-35	6865-6866	)	_	_
35-36	6867-6871	mono	_	_
35-37	6872-6891	substance-dependent	_	_
35-38	6892-6893	(	_	_
35-39	6893-6896	e.g	_	_
35-40	6896-6897	.	_	_
35-41	6897-6898	,	_	_
35-42	6899-6906	cocaine	_	_
35-43	6906-6907	,	_	_
35-44	6908-6915	opiates	_	_
35-45	6915-6916	)	_	_
35-46	6917-6927	volunteers	_	_
35-47	6927-6928	.	_	_

36-1	6929-6934	While	_	_
36-2	6935-6944	addiction	_	_
36-3	6945-6952	studies	_	_
36-4	6953-6962	typically	_	_
36-5	6963-6970	recruit	_	_
36-6	6971-6981	volunteers	_	_
36-7	6982-6984	in	_	_
36-8	6985-6990	early	_	_
36-9	6991-7001	abstinence	_	_
36-10	7001-7002	,	_	_
36-11	7003-7008	there	_	_
36-12	7009-7012	was	_	_
36-13	7013-7015	no	_	_
36-14	7016-7021	upper	_	_
36-15	7022-7027	limit	_	_
36-16	7028-7030	in	_	_
36-17	7031-7034	the	_	_
36-18	7035-7042	current	_	_
36-19	7043-7048	study	_	_
36-20	7048-7049	.	_	_

37-1	7050-7053	The	_	_
37-2	7054-7058	mean	_	_
37-3	7059-7069	abstinence	_	_
37-4	7070-7076	length	_	_
37-5	7077-7081	from	_	_
37-6	7082-7089	alcohol	_	_
37-7	7090-7092	in	_	_
37-8	7093-7096	the	_	_
37-9	7097-7104	current	_	_
37-10	7105-7111	sample	_	_
37-11	7112-7115	was	_	_
37-12	7116-7121	15.00	_	_
37-13	7121-7122	 	_	_
37-14	7122-7123	±	_	_
37-15	7123-7124	 	_	_
37-16	7124-7128	3.50	_	_
37-17	7128-7129	 	_	_
37-18	7129-7135	months	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
37-19	7135-7136	,	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
37-20	7137-7142	while	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
37-21	7143-7146	for	_	_
37-22	7147-7154	cocaine	_	_
37-23	7155-7158	and	_	_
37-24	7159-7166	opiates	_	_
37-25	7167-7169	it	_	_
37-26	7170-7173	was	_	_
37-27	7174-7179	27.99	_	_
37-28	7179-7180	 	_	_
37-29	7180-7181	±	_	_
37-30	7181-7182	 	_	_
37-31	7182-7186	3.72	_	_
37-32	7187-7190	and	_	_
37-33	7191-7196	39.04	_	_
37-34	7196-7197	 	_	_
37-35	7197-7198	±	_	_
37-36	7198-7199	 	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	_
37-37	7199-7203	7.75	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-38	7203-7204	 	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	_
37-39	7204-7210	months	_	_
37-40	7210-7211	,	_	_
37-41	7212-7224	respectively	_	_
37-42	7224-7225	.	_	_

38-1	7226-7235	Therefore	_	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-2	7235-7236	,	_	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-3	7237-7240	the	_	_
38-4	7241-7248	current	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-5	7249-7252	ADD	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-6	7253-7258	group	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-7	7259-7262	was	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-8	7263-7267	made	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-9	7268-7270	of	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-10	7271-7272	a	_	_
38-11	7273-7285	heterogenous	_	_
38-12	7286-7292	sample	_	_
38-13	7293-7297	with	_	_
38-14	7298-7304	former	_	_
38-15	7305-7327	substance-dependencies	_	_
38-16	7327-7328	,	_	_
38-17	7329-7332	and	_	_
38-18	7333-7337	with	_	_
38-19	7338-7346	variable	_	_
38-20	7347-7353	levels	_	_
38-21	7354-7356	of	_	_
38-22	7357-7366	substance	_	_
38-23	7367-7377	abstinence	_	_
38-24	7378-7380	at	_	_
38-25	7381-7384	the	_	_
38-26	7385-7389	time	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-27	7390-7392	of	_	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-28	7393-7400	testing	_	_
38-29	7400-7401	.	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging

39-1	7402-7406	This	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-2	7407-7412	meant	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-3	7413-7417	that	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-4	7418-7423	there	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-5	7424-7427	was	_	_
39-6	7428-7430	no	_	_
39-7	7431-7440	substance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
39-8	7441-7451	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
39-9	7452-7459	measure	_	_
39-10	7460-7464	that	_	_
39-11	7465-7468	was	_	_
39-12	7469-7475	shared	_	_
39-13	7476-7478	by	_	_
39-14	7479-7482	all	_	_
39-15	7483-7490	members	_	_
39-16	7491-7493	of	_	_
39-17	7494-7497	the	_	_
39-18	7498-7501	ADD	_	_
39-19	7502-7507	group	_	_
39-20	7507-7508	.	_	_

40-1	7509-7512	The	_	_
40-2	7513-7516	CON	_	_
40-3	7517-7522	group	_	_
40-4	7523-7526	had	_	_
40-5	7527-7529	no	_	_
40-6	7530-7538	previous	_	_
40-7	7539-7546	history	_	_
40-8	7547-7549	of	_	_
40-9	7550-7559	substance	_	_
40-10	7560-7565	abuse	_	_
40-11	7565-7566	,	_	_
40-12	7567-7569	as	_	_
40-13	7570-7578	assessed	_	_
40-14	7579-7584	using	_	_
40-15	7585-7588	the	_	_
40-16	7589-7596	Alcohol	_	_
40-17	7596-7597	,	_	_
40-18	7598-7605	Smoking	_	_
40-19	7606-7609	and	_	_
40-20	7610-7619	Substance	_	_
40-21	7620-7631	Involvement	_	_
40-22	7632-7641	Screening	_	_
40-23	7642-7646	Test	_	_
40-24	7647-7648	(	_	_
40-25	7648-7654	ASSIST	_	_
40-26	7654-7655	)	_	_
40-27	7656-7659	and	_	_
40-28	7660-7668	timeline	_	_
40-29	7669-7680	follow-back	_	_
40-30	7680-7681	.	_	_

41-1	7682-7685	All	_	_
41-2	7686-7698	participants	_	_
41-3	7699-7703	were	_	_
41-4	7704-7712	required	_	_
41-5	7713-7715	to	_	_
41-6	7716-7723	provide	_	_
41-7	7724-7725	a	_	_
41-8	7726-7734	negative	_	_
41-9	7735-7741	breath	_	_
41-10	7742-7749	alcohol	_	_
41-11	7750-7754	test	_	_
41-12	7755-7758	and	_	_
41-13	7759-7760	a	_	_
41-14	7761-7769	negative	_	_
41-15	7770-7775	urine	_	_
41-16	7776-7782	sample	_	_
41-17	7783-7786	for	_	_
41-18	7787-7794	various	_	_
41-19	7795-7800	drugs	_	_
41-20	7801-7803	of	_	_
41-21	7804-7809	abuse	_	_
41-22	7810-7812	on	_	_
41-23	7813-7816	the	_	_
41-24	7817-7820	day	_	_
41-25	7821-7823	of	_	_
41-26	7824-7831	testing	_	_
41-27	7832-7833	(	_	_
41-28	7833-7842	screening	_	_
41-29	7843-7846	for	_	_
41-30	7847-7850	the	_	_
41-31	7851-7859	presence	_	_
41-32	7860-7862	of	_	_
41-33	7863-7875	amphetamines	_	_
41-34	7875-7876	,	_	_
41-35	7877-7892	benzodiazepines	_	_
41-36	7892-7893	,	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-37	7894-7906	cannabinoids	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-38	7906-7907	,	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-39	7908-7915	cocaine	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-40	7916-7919	and	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-41	7920-7927	opiates	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-42	7927-7928	)	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-43	7928-7929	.	_	_

42-1	7930-7933	The	_	_
42-2	7934-7952	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
42-3	7953-7969	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
42-4	7970-7979	Interview	_	_
42-5	7980-7981	(	_	_
42-6	7981-7985	MINI	_	_
42-7	7985-7986	)	_	_
42-8	7987-7990	was	_	_
42-9	7991-8003	administered	_	_
42-10	8004-8006	to	_	_
42-11	8007-8010	all	_	_
42-12	8011-8023	participants	_	_
42-13	8024-8026	by	_	_
42-14	8027-8028	a	_	_
42-15	8029-8036	trained	_	_
42-16	8037-8049	psychiatrist	_	_
42-17	8050-8052	to	_	_
42-18	8053-8059	screen	_	_
42-19	8060-8063	for	_	_
42-20	8064-8067	the	_	_
42-21	8068-8076	presence	_	_
42-22	8077-8079	of	_	_
42-23	8080-8084	Axis	_	_
42-24	8085-8086	I	_	_
42-25	8087-8098	psychiatric	_	_
42-26	8099-8108	disorders	_	_
42-27	8109-8113	that	_	_
42-28	8114-8118	were	_	_
42-29	8119-8123	part	_	_
42-30	8124-8126	of	_	_
42-31	8127-8130	the	_	_
42-32	8131-8136	study	_	_
42-33	8137-8146	exclusion	_	_
42-34	8147-8155	criteria	_	_
42-35	8155-8156	.	_	_

43-1	8157-8166	Exclusion	_	_
43-2	8167-8175	criteria	_	_
43-3	8176-8184	included	_	_
43-4	8185-8186	1	_	_
43-5	8186-8187	)	_	_
43-6	8188-8195	current	_	_
43-7	8196-8199	use	_	_
43-8	8200-8202	of	_	_
43-9	8203-8210	regular	_	_
43-10	8211-8223	prescription	_	_
43-11	8224-8226	or	_	_
43-12	8227-8243	non-prescription	_	_
43-13	8244-8254	medication	_	_
43-14	8255-8259	that	_	_
43-15	8260-8265	could	_	_
43-16	8266-8269	not	_	_
43-17	8270-8272	be	_	_
43-18	8273-8280	stopped	_	_
43-19	8280-8281	;	_	_
43-20	8282-8283	2	_	_
43-21	8283-8284	)	_	_
43-22	8285-8292	current	_	_
43-23	8293-8300	primary	_	_
43-24	8301-8305	axis	_	_
43-25	8306-8307	I	_	_
43-26	8308-8317	diagnosis	_	_
43-27	8317-8318	,	_	_
43-28	8319-8323	past	_	_
43-29	8324-8331	history	_	_
43-30	8332-8334	of	_	_
43-31	8335-8344	psychosis	_	_
43-32	8345-8346	(	_	_
43-33	8346-8352	unless	_	_
43-34	8353-8365	drug-induced	_	_
43-35	8365-8366	)	_	_
43-36	8366-8367	;	_	_
43-37	8368-8369	3	_	_
43-38	8369-8370	)	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-39	8371-8378	current	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-40	8379-8381	or	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-41	8382-8386	past	_	_
43-42	8387-8394	history	_	_
43-43	8395-8397	of	_	_
43-44	8398-8406	enduring	_	_
43-45	8407-8413	severe	_	_
43-46	8414-8420	mental	_	_
43-47	8421-8428	illness	_	_
43-48	8429-8430	(	_	_
43-49	8430-8433	e.g	_	_
43-50	8433-8434	.	_	_
43-51	8434-8435	,	_	_
43-52	8436-8449	schizophrenia	_	_
43-53	8449-8450	,	_	_
43-54	8451-8458	bipolar	_	_
43-55	8459-8468	affective	_	_
43-56	8469-8477	disorder	_	_
43-57	8477-8478	)	_	_
43-58	8478-8479	;	_	_
43-59	8480-8481	4	_	_
43-60	8481-8482	)	_	_
43-61	8483-8488	other	_	_
43-62	8489-8496	current	_	_
43-63	8497-8499	or	_	_
43-64	8500-8504	past	_	_
43-65	8505-8516	psychiatric	_	_
43-66	8517-8524	history	_	_
43-67	8525-8529	that	_	_
43-68	8529-8530	,	_	_
43-69	8531-8533	in	_	_
43-70	8534-8537	the	_	_
43-71	8538-8545	opinion	_	_
43-72	8546-8548	of	_	_
43-73	8549-8550	a	_	_
43-74	8551-8563	psychiatrist	_	_
43-75	8563-8564	,	_	_
43-76	8565-8580	contraindicated	_	_
43-77	8581-8594	participation	_	_
43-78	8594-8595	;	_	_
43-79	8596-8597	5	_	_
43-80	8597-8598	)	_	_
43-81	8599-8606	history	_	_
43-82	8607-8609	or	_	_
43-83	8610-8618	presence	_	_
43-84	8619-8621	of	_	_
43-85	8622-8623	a	_	_
43-86	8624-8635	significant	_	_
43-87	8636-8648	neurological	_	_
43-88	8649-8658	diagnosis	_	_
43-89	8659-8663	that	_	_
43-90	8664-8667	may	_	_
43-91	8668-8672	have	_	_
43-92	8673-8683	influenced	_	_
43-93	8684-8687	the	_	_
43-94	8688-8695	outcome	_	_
43-95	8696-8698	or	_	_
43-96	8699-8707	analysis	_	_
43-97	8708-8710	of	_	_
43-98	8711-8714	the	_	_
43-99	8715-8722	results	_	_
43-100	8722-8723	;	_	_
43-101	8724-8725	6	_	_
43-102	8725-8726	)	_	_
43-103	8727-8741	claustrophobia	_	_
43-104	8742-8744	or	_	_
43-105	8745-8751	unable	_	_
43-106	8752-8754	to	_	_
43-107	8755-8758	lie	_	_
43-108	8759-8764	still	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
43-109	8765-8767	in	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
43-110	8768-8771	the	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
43-111	8772-8775	MRI	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
43-112	8776-8783	scanner	_	_
43-113	8784-8787	for	_	_
43-114	8788-8790	up	_	_
43-115	8791-8793	to	_	_
43-116	8794-8796	90	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-117	8796-8797	 	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-118	8797-8800	min	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-119	8801-8804	and	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-120	8805-8806	7	_	_
43-121	8806-8807	)	_	_
43-122	8808-8816	presence	_	_
43-123	8817-8819	of	_	_
43-124	8820-8821	a	_	_
43-125	8822-8829	cardiac	_	_
43-126	8830-8839	pacemaker	_	_
43-127	8839-8840	,	_	_
43-128	8841-8846	other	_	_
43-129	8847-8857	electronic	_	_
43-130	8858-8864	device	_	_
43-131	8865-8867	or	_	_
43-132	8868-8873	other	_	_
43-133	8874-8877	MRI	_	_
43-134	8878-8894	contraindication	_	_
43-135	8894-8895	,	_	_
43-136	8896-8905	including	_	_
43-137	8906-8915	pregnancy	_	_
43-138	8915-8916	,	_	_
43-139	8917-8919	as	_	_
43-140	8920-8928	assessed	_	_
43-141	8929-8931	by	_	_
43-142	8932-8933	a	_	_
43-143	8934-8942	standard	_	_
43-144	8943-8950	pre-MRI	_	_
43-145	8951-8964	questionnaire	_	_
43-146	8964-8965	.	_	_

44-1	8966-8975	Secondary	_	_
44-2	8976-8978	or	_	_
44-3	8979-8987	lifetime	_	_
44-4	8988-8995	history	_	_
44-5	8996-8998	of	_	_
44-6	8999-9009	depression	_	_
44-7	9010-9012	or	_	_
44-8	9013-9020	anxiety	_	_
44-9	9021-9024	was	_	_
44-10	9025-9034	permitted	_	_
44-11	9035-9037	in	_	_
44-12	9038-9042	both	_	_
44-13	9043-9046	the	_	_
44-14	9047-9050	ADD	_	_
44-15	9051-9054	and	_	_
44-16	9055-9058	CON	_	_
44-17	9059-9065	groups	_	_
44-18	9066-9071	since	_	_
44-19	9072-9077	these	_	_
44-20	9078-9081	are	_	_
44-21	9082-9086	very	_	_
44-22	9087-9093	common	_	_
44-23	9094-9105	psychiatric	_	_
44-24	9106-9115	disorders	_	_
44-25	9115-9116	.	_	_

45-1	9117-9120	All	_	_
45-2	9121-9133	participants	_	_
45-3	9134-9142	provided	_	_
45-4	9143-9150	written	_	_
45-5	9151-9159	informed	_	_
45-6	9160-9167	consent	_	_
45-7	9167-9168	.	_	_

46-1	9169-9172	The	_	_
46-2	9173-9178	study	_	_
46-3	9179-9182	was	_	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
46-4	9183-9192	conducted	_	_
46-5	9193-9195	in	_	_
46-6	9196-9206	accordance	_	_
46-7	9207-9211	with	_	_
46-8	9212-9215	the	_	_
46-9	9216-9227	Declaration	_	_
46-10	9228-9230	of	_	_
46-11	9231-9239	Helsinki	_	_
46-12	9239-9240	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging

47-1	9241-9248	Ethical	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	_
47-2	9249-9257	approval	_	_
47-3	9258-9261	was	_	_
47-4	9262-9270	obtained	_	_
47-5	9271-9275	from	_	_
47-6	9276-9280	West	_	_
47-7	9281-9287	London	_	_
47-8	9288-9291	and	_	_
47-9	9292-9296	Gene	_	_
47-10	9297-9304	Therapy	_	_
47-11	9305-9313	Advisory	_	_
47-12	9314-9323	Committee	_	_
47-13	9324-9332	National	_	_
47-14	9333-9341	Research	_	_
47-15	9342-9348	Ethics	_	_
47-16	9349-9356	Service	_	_
47-17	9357-9366	Committee	_	_
47-18	9367-9368	(	_	_
47-19	9368-9370	11	_	_
47-20	9370-9371	/	_	_
47-21	9371-9376	H0707	_	_
47-22	9376-9377	/	_	_
47-23	9377-9378	9	_	_
47-24	9378-9379	)	_	_
47-25	9380-9383	and	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
47-26	9384-9392	relevant	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
47-27	9393-9401	research	_	_
47-28	9402-9412	governance	_	_
47-29	9413-9416	and	_	_
47-30	9417-9428	Participant	_	_
47-31	9429-9443	Identification	_	_
47-32	9444-9450	Centre	_	_
47-33	9451-9452	(	_	_
47-34	9452-9455	PIC	_	_
47-35	9455-9456	)	_	_
47-36	9457-9466	approvals	_	_
47-37	9467-9475	obtained	_	_
47-38	9475-9476	.	_	_

48-1	9477-9485	Monetary	_	_
48-2	9486-9495	incentive	_	_
48-3	9496-9501	delay	_	_
48-4	9502-9506	task	_	_
48-5	9507-9508	(	_	_
48-6	9508-9511	MID	_	_
48-7	9511-9512	)	_	_
48-8	9513-9515	We	_	_
48-9	9516-9520	used	_	_
48-10	9521-9522	a	_	_
48-11	9523-9524	“	_	_
48-12	9524-9532	monetary	_	_
48-13	9533-9542	incentive	_	_
48-14	9543-9548	delay	_	_
48-15	9549-9553	task	_	_
48-16	9553-9554	”	_	_
48-17	9555-9556	(	_	_
48-18	9556-9559	MID	_	_
48-19	9559-9560	)	_	_
48-20	9560-9561	,	_	_
48-21	9562-9567	which	_	_
48-22	9568-9571	was	_	_
48-23	9572-9577	based	_	_
48-24	9578-9580	on	_	_
48-25	9581-9585	that	_	_
48-26	9586-9596	originally	_	_
48-27	9597-9605	employed	_	_
48-28	9606-9608	by	_	_
48-29	9609-9616	Knutson	_	_
48-30	9616-9617	,	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
48-31	9618-9621	and	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
48-32	9622-9627	which	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
48-33	9628-9630	we	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
48-34	9631-9635	have	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
48-35	9636-9640	used	_	_
48-36	9641-9643	to	_	_
48-37	9644-9651	already	_	_
48-38	9652-9659	publish	_	_
48-39	9660-9664	data	_	_
48-40	9665-9669	from	_	_
48-41	9670-9673	the	_	_
48-42	9674-9679	ICCAM	_	_
48-43	9680-9688	platform	_	_
48-44	9688-9689	.	_	_

49-1	9690-9692	At	_	_
49-2	9693-9696	the	_	_
49-3	9697-9706	beginning	_	_
49-4	9707-9709	of	_	_
49-5	9710-9714	each	_	_
49-6	9715-9720	trial	_	_
49-7	9720-9721	,	_	_
49-8	9722-9734	participants	_	_
49-9	9735-9741	viewed	_	_
49-10	9742-9745	one	_	_
49-11	9746-9748	of	_	_
49-12	9749-9754	three	_	_
49-13	9755-9762	symbols	_	_
49-14	9763-9764	(	_	_
49-15	9764-9765	a	_	_
49-16	9766-9769	cue	_	_
49-17	9769-9770	)	_	_
49-18	9771-9775	that	_	_
49-19	9776-9785	indicated	_	_
49-20	9786-9789	the	_	_
49-21	9790-9799	potential	_	_
49-22	9800-9802	to	_	_
49-23	9803-9807	gain	_	_
49-24	9808-9813	fifty	_	_
49-25	9814-9819	pence	_	_
49-26	9820-9821	(	_	_
49-27	9821-9827	square	_	_
49-28	9828-9838	containing	_	_
49-29	9839-9841	an	_	_
49-30	9842-9851	ascending	_	_
49-31	9852-9857	arrow	_	_
49-32	9857-9858	)	_	_
49-33	9858-9859	,	_	_
49-34	9860-9864	lose	_	_
49-35	9865-9870	fifty	_	_
49-36	9871-9876	pence	_	_
49-37	9877-9878	(	_	_
49-38	9878-9884	square	_	_
49-39	9885-9895	containing	_	_
49-40	9896-9897	a	_	_
49-41	9898-9908	descending	_	_
49-42	9909-9914	arrow	_	_
49-43	9914-9915	)	_	_
49-44	9916-9918	or	_	_
49-45	9919-9929	experience	_	_
49-46	9930-9932	no	_	_
49-47	9933-9942	financial	_	_
49-48	9943-9950	outcome	_	_
49-49	9951-9952	(	_	_
49-50	9952-9958	square	_	_
49-51	9959-9969	containing	_	_
49-52	9970-9971	a	_	_
49-53	9972-9982	horizontal	_	_
49-54	9983-9987	line	_	_
49-55	9988-9989	-	_	_
49-56	9990-9994	here	_	_
49-57	9995-10003	referred	_	_
49-58	10004-10006	to	_	_
49-59	10007-10009	as	_	_
49-60	10010-10011	a	_	_
49-61	10012-10019	neutral	_	_
49-62	10020-10025	trial	_	_
49-63	10025-10026	)	_	_
49-64	10026-10027	.	_	_

50-1	10028-10032	Each	_	_
50-2	10033-10036	cue	_	_
50-3	10037-10040	was	_	_
50-4	10041-10050	presented	_	_
50-5	10051-10054	for	_	_
50-6	10055-10058	one	_	_
50-7	10059-10065	second	_	_
50-8	10065-10066	,	_	_
50-9	10067-10071	with	_	_
50-10	10072-10073	a	_	_
50-11	10074-10082	variable	_	_
50-12	10083-10091	duration	_	_
50-13	10092-10093	(	_	_
50-14	10093-10094	2	_	_
50-15	10094-10095	–	_	_
50-16	10095-10096	4	_	_
50-17	10096-10097	 	_	_
50-18	10097-10098	s	_	_
50-19	10098-10099	)	_	_
50-20	10100-10103	for	_	_
50-21	10104-10107	the	_	_
50-22	10108-10118	subsequent	_	_
50-23	10119-10131	anticipation	_	_
50-24	10132-10138	period	_	_
50-25	10138-10139	.	_	_

51-1	10140-10149	Following	_	_
51-2	10150-10153	the	_	_
51-3	10154-10166	anticipation	_	_
51-4	10167-10173	period	_	_
51-5	10173-10174	,	_	_
51-6	10175-10187	participants	_	_
51-7	10188-10192	made	_	_
51-8	10193-10194	a	_	_
51-9	10195-10201	button	_	_
51-10	10202-10207	press	_	_
51-11	10208-10216	response	_	_
51-12	10217-10221	upon	_	_
51-13	10222-10225	the	_	_
51-14	10226-10238	presentation	_	_
51-15	10239-10241	of	_	_
51-16	10242-10243	a	_	_
51-17	10244-10250	visual	_	_
51-18	10251-10257	target	_	_
51-19	10258-10259	(	_	_
51-20	10259-10263	star	_	_
51-21	10264-10271	located	_	_
51-22	10272-10278	within	_	_
51-23	10279-10280	a	_	_
51-24	10281-10287	circle	_	_
51-25	10287-10288	)	_	_
51-26	10288-10289	.	_	_

52-1	10290-10299	Following	_	_
52-2	10300-10305	their	_	_
52-3	10306-10314	response	_	_
52-4	10315-10317	to	_	_
52-5	10318-10321	the	_	_
52-6	10322-10328	visual	_	_
52-7	10329-10335	target	_	_
52-8	10335-10336	,	_	_
52-9	10337-10349	participants	_	_
52-10	10350-10358	received	_	_
52-11	10359-10367	feedback	_	_
52-12	10368-10369	(	_	_
52-13	10369-10372	1.5	_	_
52-14	10372-10373	 	_	_
52-15	10373-10374	s	_	_
52-16	10374-10375	)	_	_
52-17	10376-10378	as	_	_
52-18	10379-10381	to	_	_
52-19	10382-10389	whether	_	_
52-20	10390-10394	they	_	_
52-21	10395-10399	were	_	_
52-22	10400-10410	successful	_	_
52-23	10411-10412	(	_	_
52-24	10412-10413	“	_	_
52-25	10413-10416	Hit	_	_
52-26	10416-10417	”	_	_
52-27	10417-10418	)	_	_
52-28	10419-10421	or	_	_
52-29	10422-10434	unsuccessful	_	_
52-30	10435-10436	(	_	_
52-31	10436-10437	“	_	_
52-32	10437-10441	Miss	_	_
52-33	10441-10442	”	_	_
52-34	10442-10443	)	_	_
52-35	10444-10446	on	_	_
52-36	10447-10451	that	_	_
52-37	10452-10457	trial	_	_
52-38	10458-10461	and	_	_
52-39	10462-10465	saw	_	_
52-40	10466-10467	a	_	_
52-41	10468-10475	running	_	_
52-42	10476-10481	total	_	_
52-43	10482-10484	of	_	_
52-44	10485-10490	their	_	_
52-45	10491-10499	winnings	_	_
52-46	10500-10502	up	_	_
52-47	10503-10505	to	_	_
52-48	10506-10510	that	_	_
52-49	10511-10516	point	_	_
52-50	10517-10519	in	_	_
52-51	10520-10523	the	_	_
52-52	10524-10528	task	_	_
52-53	10528-10529	.	_	_

53-1	10530-10539	Following	_	_
53-2	10540-10548	feedback	_	_
53-3	10548-10549	,	_	_
53-4	10550-10555	there	_	_
53-5	10556-10559	was	_	_
53-6	10560-10562	an	_	_
53-7	10563-10566	end	_	_
53-8	10567-10575	fixation	_	_
53-9	10576-10582	period	_	_
53-10	10583-10584	(	_	_
53-11	10584-10585	3	_	_
53-12	10585-10586	–	_	_
53-13	10586-10587	5	_	_
53-14	10587-10588	 	_	_
53-15	10588-10589	s	_	_
53-16	10589-10590	)	_	_
53-17	10591-10597	before	_	_
53-18	10598-10601	the	_	_
53-19	10602-10614	commencement	_	_
53-20	10615-10617	of	_	_
53-21	10618-10621	the	_	_
53-22	10622-10626	next	_	_
53-23	10627-10632	trial	_	_
53-24	10632-10633	.	_	_

54-1	10634-10641	Because	_	_
54-2	10642-10645	the	_	_
54-3	10646-10653	primary	_	_
54-4	10654-10663	objective	_	_
54-5	10664-10666	of	_	_
54-6	10667-10672	ICCAM	_	_
54-7	10673-10676	was	_	_
54-8	10677-10679	to	_	_
54-9	10680-10687	examine	_	_
54-10	10688-10691	the	_	_
54-11	10692-10698	neural	_	_
54-12	10699-10709	correlates	_	_
54-13	10710-10712	of	_	_
54-14	10713-10719	reward	_	_
54-15	10720-10732	anticipation	_	_
54-16	10732-10733	,	_	_
54-17	10734-10736	we	_	_
54-18	10737-10742	chose	_	_
54-19	10743-10745	to	_	_
54-20	10746-10749	use	_	_
54-21	10750-10751	a	_	_
54-22	10752-10759	smaller	_	_
54-23	10760-10766	number	_	_
54-24	10767-10769	of	_	_
54-25	10770-10774	loss	_	_
54-26	10775-10781	trials	_	_
54-27	10782-10784	in	_	_
54-28	10785-10790	order	_	_
54-29	10791-10793	to	_	_
54-30	10794-10801	amplify	_	_
54-31	10802-10805	the	_	_
54-32	10806-10815	incentive	_	_
54-33	10816-10824	salience	_	_
54-34	10825-10827	of	_	_
54-35	10828-10831	the	_	_
54-36	10832-10836	gain	_	_
54-37	10837-10843	trials	_	_
54-38	10844-10850	during	_	_
54-39	10851-10854	the	_	_
54-40	10855-10859	task	_	_
54-41	10859-10860	.	_	_

55-1	10861-10873	Consequently	_	_
55-2	10873-10874	,	_	_
55-3	10875-10880	there	_	_
55-4	10881-10884	was	_	_
55-5	10885-10886	a	_	_
55-6	10887-10892	total	_	_
55-7	10893-10895	of	_	_
55-8	10896-10898	18	_	_
55-9	10899-10903	gain	_	_
55-10	10903-10904	,	_	_
55-11	10905-10906	6	_	_
55-12	10907-10911	lose	_	_
55-13	10912-10915	and	_	_
55-14	10916-10918	18	_	_
55-15	10919-10926	neutral	_	_
55-16	10927-10933	trials	_	_
55-17	10934-10936	on	_	_
55-18	10937-10941	each	_	_
55-19	10942-10945	run	_	_
55-20	10946-10948	of	_	_
55-21	10949-10952	the	_	_
55-22	10953-10957	task	_	_
55-23	10957-10958	.	_	_

56-1	10959-10962	The	_	_
56-2	10963-10966	MID	_	_
56-3	10967-10971	task	_	_
56-4	10972-10975	was	_	_
56-5	10976-10984	tailored	_	_
56-6	10985-10987	to	_	_
56-7	10988-10993	adapt	_	_
56-8	10994-10996	to	_	_
56-9	10997-11000	the	_	_
56-10	11001-11007	visual	_	_
56-11	11008-11014	target	_	_
56-12	11015-11023	reaction	_	_
56-13	11024-11028	time	_	_
56-14	11029-11031	of	_	_
56-15	11032-11036	each	_	_
56-16	11037-11048	participant	_	_
56-17	11049-11051	by	_	_
56-18	11052-11057	using	_	_
56-19	11058-11059	a	_	_
56-20	11060-11069	staircase	_	_
56-21	11070-11079	algorithm	_	_
56-22	11079-11080	,	_	_
56-23	11081-11085	such	_	_
56-24	11086-11090	that	_	_
56-25	11091-11094	the	_	_
56-26	11095-11107	presentation	_	_
56-27	11108-11110	of	_	_
56-28	11111-11114	the	_	_
56-29	11115-11121	visual	_	_
56-30	11122-11128	target	_	_
56-31	11129-11135	became	_	_
56-32	11136-11143	shorter	_	_
56-33	11144-11146	as	_	_
56-34	11147-11158	performance	_	_
56-35	11159-11167	improved	_	_
56-36	11168-11174	during	_	_
56-37	11175-11178	the	_	_
56-38	11179-11189	experiment	_	_
56-39	11189-11190	.	_	_

57-1	11191-11195	This	_	_
57-2	11196-11203	enabled	_	_
57-3	11204-11206	us	_	_
57-4	11207-11209	to	_	_
57-5	11210-11213	set	_	_
57-6	11214-11215	a	_	_
57-7	11216-11221	limit	_	_
57-8	11222-11224	on	_	_
57-9	11225-11228	the	_	_
57-10	11229-11236	success	_	_
57-11	11237-11241	rate	_	_
57-12	11242-11244	of	_	_
57-13	11245-11249	each	_	_
57-14	11250-11261	participant	_	_
57-15	11262-11263	(	_	_
57-16	11263-11264	∼	_	_
57-17	11264-11267	66%	_	_
57-18	11267-11268	)	_	_
57-19	11268-11269	,	_	_
57-20	11270-11275	which	_	_
57-21	11276-11288	additionally	_	_
57-22	11289-11295	served	_	_
57-23	11296-11298	to	_	_
57-24	11299-11310	incentivize	_	_
57-25	11311-11323	participants	_	_
57-26	11324-11326	to	_	_
57-27	11327-11333	engage	_	_
57-28	11334-11336	in	_	_
57-29	11337-11340	the	_	_
57-30	11341-11345	task	_	_
57-31	11345-11346	.	_	_

58-1	11347-11359	Participants	_	_
58-2	11360-11364	were	_	_
58-3	11365-11375	instructed	_	_
58-4	11376-11378	to	_	_
58-5	11379-11387	maximize	_	_
58-6	11388-11393	their	_	_
58-7	11394-11402	winnings	_	_
58-8	11403-11406	and	_	_
58-9	11407-11411	were	_	_
58-10	11412-11416	told	_	_
58-11	11417-11421	they	_	_
58-12	11422-11427	would	_	_
58-13	11428-11435	receive	_	_
58-14	11436-11440	them	_	_
58-15	11441-11443	at	_	_
58-16	11444-11447	the	_	_
58-17	11448-11451	end	_	_
58-18	11452-11454	of	_	_
58-19	11455-11458	the	_	_
58-20	11459-11464	study	_	_
58-21	11464-11465	.	_	_

59-1	11466-11475	Dependent	_	_
59-2	11476-11484	measures	_	_
59-3	11485-11489	were	_	_
59-4	11490-11498	accuracy	_	_
59-5	11499-11500	(	_	_
59-6	11500-11510	percentage	_	_
59-7	11510-11511	)	_	_
59-8	11512-11515	and	_	_
59-9	11516-11520	mean	_	_
59-10	11521-11529	reaction	_	_
59-11	11530-11534	time	_	_
59-12	11535-11536	(	_	_
59-13	11536-11548	milliseconds	_	_
59-14	11548-11549	)	_	_
59-15	11550-11552	to	_	_
59-16	11553-11556	the	_	_
59-17	11557-11563	visual	_	_
59-18	11564-11570	target	_	_
59-19	11571-11573	on	_	_
59-20	11574-11578	each	_	_
59-21	11579-11581	of	_	_
59-22	11582-11585	the	_	_
59-23	11586-11590	gain	_	_
59-24	11590-11591	,	_	_
59-25	11592-11596	lose	_	_
59-26	11597-11600	and	_	_
59-27	11601-11608	neutral	_	_
59-28	11609-11615	trials	_	_
59-29	11615-11616	,	_	_
59-30	11617-11620	and	_	_
59-31	11621-11624	the	_	_
59-32	11625-11631	amount	_	_
59-33	11632-11635	won	_	_
59-34	11636-11637	(	_	_
59-35	11637-11638	£	_	_
59-36	11638-11639	)	_	_
59-37	11640-11642	on	_	_
59-38	11643-11646	the	_	_
59-39	11647-11651	task	_	_
59-40	11651-11652	.	_	_

60-1	11653-11665	Participants	_	_
60-2	11666-11675	completed	_	_
60-3	11676-11679	two	_	_
60-4	11680-11684	runs	_	_
60-5	11685-11687	of	_	_
60-6	11688-11691	the	_	_
60-7	11692-11696	task	_	_
60-8	11697-11698	(	_	_
60-9	11698-11701	432	_	_
60-10	11701-11702	 	_	_
60-11	11702-11703	s	_	_
60-12	11704-11708	each	_	_
60-13	11708-11709	)	_	_
60-14	11710-11716	during	_	_
60-15	11717-11725	scanning	_	_
60-16	11725-11726	.	_	_

61-1	11727-11730	The	_	_
61-2	11731-11735	task	_	_
61-3	11736-11739	was	_	_
61-4	11740-11750	programmed	_	_
61-5	11751-11756	using	_	_
61-6	11757-11764	E-Prime	_	_
61-7	11765-11772	version	_	_
61-8	11773-11776	2.0	_	_
61-9	11777-11778	(	_	_
61-10	11778-11788	Psychology	_	_
61-11	11789-11797	Software	_	_
61-12	11798-11803	Tools	_	_
61-13	11803-11804	,	_	_
61-14	11805-11815	Pittsburgh	_	_
61-15	11815-11816	,	_	_
61-16	11817-11820	USA	_	_
61-17	11820-11821	)	_	_
61-18	11821-11822	.	_	_

62-1	11823-11833	Statistics	_	_
62-2	11834-11839	Group	_	_
62-3	11840-11852	demographics	_	_
62-4	11853-11857	were	_	_
62-5	11858-11866	compared	_	_
62-6	11867-11872	using	_	_
62-7	11873-11879	simple	_	_
62-8	11880-11891	independent	_	_
62-9	11892-11899	samples	_	_
62-10	11900-11906	t-test	_	_
62-11	11907-11915	analyses	_	_
62-12	11915-11916	.	_	_

63-1	11917-11920	For	_	_
63-2	11921-11929	analyses	_	_
63-3	11930-11939	conducted	_	_
63-4	11940-11942	on	_	_
63-5	11943-11946	MID	_	_
63-6	11947-11958	performance	_	_
63-7	11958-11959	,	_	_
63-8	11960-11963	two	_	_
63-9	11964-11965	(	_	_
63-10	11965-11970	Group	_	_
63-11	11970-11971	:	_	_
63-12	11972-11975	CON	_	_
63-13	11976-11978	vs	_	_
63-14	11978-11979	.	_	_

64-1	11980-11983	ADD	_	_
64-2	11983-11984	)	_	_
64-3	11985-11987	by	_	_
64-4	11988-11991	two	_	_
64-5	11992-11993	(	_	_
64-6	11993-12002	Condition	_	_
64-7	12002-12003	:	_	_
64-8	12004-12008	Gain	_	_
64-9	12009-12011	vs	_	_
64-10	12011-12012	.	_	_

65-1	12013-12020	Neutral	_	_
65-2	12020-12021	)	_	_
65-3	12022-12030	analyses	_	_
65-4	12031-12033	of	_	_
65-5	12034-12042	variance	_	_
65-6	12043-12047	were	_	_
65-7	12048-12057	conducted	_	_
65-8	12057-12058	.	_	_

66-1	12059-12062	The	_	_
66-2	12063-12066	CON	_	_
66-3	12067-12070	and	_	_
66-4	12071-12074	ADD	_	_
66-5	12075-12081	groups	_	_
66-6	12082-12086	were	_	_
66-7	12087-12091	also	_	_
66-8	12092-12100	compared	_	_
66-9	12101-12103	on	_	_
66-10	12104-12107	the	_	_
66-11	12108-12112	lose	_	_
66-12	12113-12121	accuracy	_	_
66-13	12122-12125	and	_	_
66-14	12126-12130	lose	_	_
66-15	12131-12139	reaction	_	_
66-16	12140-12144	time	_	_
66-17	12145-12156	performance	_	_
66-18	12157-12165	measures	_	_
66-19	12165-12166	,	_	_
66-20	12167-12169	as	_	_
66-21	12170-12174	well	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
66-22	12175-12177	as	_	_
66-23	12178-12181	the	_	_
66-24	12182-12188	amount	_	_
66-25	12189-12191	of	_	_
66-26	12192-12197	money	_	_
66-27	12198-12201	won	_	_
66-28	12202-12203	(	_	_
66-29	12203-12204	£	_	_
66-30	12204-12205	)	_	_
66-31	12205-12206	,	_	_
66-32	12207-12212	using	_	_
66-33	12213-12221	analyses	_	_
66-34	12222-12224	of	_	_
66-35	12225-12233	variance	_	_
66-36	12233-12234	.	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse

67-1	12235-12240	These	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
67-2	12241-12249	analyses	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-3	12250-12254	were	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-4	12255-12264	conducted	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-5	12265-12276	controlling	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-6	12277-12280	for	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-7	12281-12286	study	_	_
67-8	12287-12291	site	_	_
67-9	12291-12292	.	_	_

68-1	12293-12296	For	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-2	12297-12300	the	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-3	12301-12306	graph	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-4	12307-12315	measures	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-5	12316-12317	(	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-6	12317-12320	see	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-7	12321-12326	below	_	_
68-8	12326-12327	)	_	_
68-9	12328-12330	we	_	_
68-10	12331-12340	conducted	_	_
68-11	12341-12344	two	_	_
68-12	12345-12346	(	_	_
68-13	12346-12351	Group	_	_
68-14	12351-12352	:	_	_
68-15	12353-12356	CON	_	_
68-16	12357-12359	vs	_	_
68-17	12359-12360	.	_	_

69-1	12361-12364	ADD	_	_
69-2	12364-12365	)	_	_
69-3	12366-12368	by	_	_
69-4	12369-12373	five	_	_
69-5	12374-12375	(	_	_
69-6	12375-12376	1	_	_
69-7	12376-12377	 	_	_
69-8	12377-12378	⩽	_	_
69-9	12378-12379	 	_	_
69-10	12379-12380	K	_	_
69-11	12380-12381	 	_	_
69-12	12381-12382	⩽	_	_
69-13	12382-12383	 	_	_
69-14	12383-12384	5	_	_
69-15	12384-12385	)	_	_
69-16	12386-12394	analyses	_	_
69-17	12395-12397	of	_	_
69-18	12398-12406	variance	_	_
69-19	12406-12407	,	_	_
69-20	12408-12413	while	_	_
69-21	12414-12418	also	_	_
69-22	12419-12430	controlling	_	_
69-23	12431-12434	for	_	_
69-24	12435-12440	study	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
69-25	12441-12445	site	_	_
69-26	12445-12446	.	_	_

70-1	12447-12450	All	_	_
70-2	12451-12456	these	_	_
70-3	12457-12465	analyses	_	_
70-4	12466-12470	were	_	_
70-5	12471-12480	conducted	_	_
70-6	12481-12486	using	_	_
70-7	12487-12498	permutation	_	_
70-8	12499-12506	testing	_	_
70-9	12507-12508	(	_	_
70-10	12508-12512	5000	_	_
70-11	12513-12523	iterations	_	_
70-12	12523-12524	)	_	_
70-13	12525-12527	in	_	_
70-14	12528-12531	the	_	_
70-15	12532-12533	R	_	_
70-16	12534-12545	statistical	_	_
70-17	12546-12554	software	_	_
70-18	12555-12562	package	_	_
70-19	12563-12564	(	_	_
70-20	12564-12581	www.R-project.org	_	_
70-21	12581-12582	)	_	_
70-22	12582-12583	.	_	_

71-1	12584-12594	Functional	_	_
71-2	12595-12598	MRI	_	_
71-3	12599-12600	(	_	_
71-4	12600-12604	fMRI	_	_
71-5	12604-12605	)	_	_
71-6	12606-12610	Data	_	_
71-7	12611-12622	acquisition	_	_
71-8	12623-12626	The	_	_
71-9	12627-12632	ICCAM	_	_
71-10	12633-12641	platform	_	_
71-11	12642-12645	was	_	_
71-12	12646-12654	designed	_	_
71-13	12655-12657	to	_	_
71-14	12658-12663	allow	_	_
71-15	12664-12667	the	_	_
71-16	12668-12673	rapid	_	_
71-17	12674-12681	testing	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
71-18	12682-12688	across	_	_
71-19	12689-12694	sites	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
71-20	12695-12697	of	_	_
71-21	12698-12706	multiple	_	_
71-22	12707-12716	compounds	_	_
71-23	12717-12725	relevant	_	_
71-24	12726-12728	to	_	_
71-25	12729-12738	addiction	_	_
71-26	12739-12748	treatment	_	_
71-27	12748-12749	.	_	_

72-1	12750-12757	Imaging	_	_
72-2	12758-12760	at	_	_
72-3	12761-12769	multiple	_	_
72-4	12770-12775	sites	_	_
72-5	12776-12778	in	_	_
72-6	12779-12787	parallel	_	_
72-7	12788-12790	on	_	_
72-8	12791-12794	the	_	_
72-9	12795-12800	ICCAM	_	_
72-10	12801-12809	platform	_	_
72-11	12810-12821	accelerated	_	_
72-12	12822-12827	study	_	_
72-13	12828-12838	completion	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
72-14	12838-12839	,	_	_
72-15	12840-12847	through	_	_
72-16	12848-12851	the	_	_
72-17	12852-12859	sharing	_	_
72-18	12860-12862	of	_	_
72-19	12863-12872	expertise	_	_
72-20	12872-12873	,	_	_
72-21	12874-12888	infrastructure	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
72-22	12889-12892	and	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
72-23	12893-12901	capacity	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
72-24	12901-12902	.	_	_
72-25	12902-12903	 	_	_

73-1	12903-12906	For	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
73-2	12907-12908	a	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
73-3	12909-12913	more	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
73-4	12914-12927	comprehensive	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
73-5	12928-12939	description	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
73-6	12940-12942	of	_	_
73-7	12943-12947	data	_	_
73-8	12948-12959	acquisition	_	_
73-9	12960-12966	across	_	_
73-10	12967-12970	the	_	_
73-11	12971-12976	three	_	_
73-12	12977-12982	sites	_	_
73-13	12983-12985	on	_	_
73-14	12986-12991	ICCAM	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
73-15	12991-12992	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
73-16	12993-12999	please	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
73-17	13000-13003	see	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
73-18	13004-13013	McGonigle	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
73-19	13014-13016	et	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
73-20	13017-13019	al	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
73-21	13019-13020	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging

74-1	13021-13028	Briefly	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
74-2	13028-13029	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
74-3	13030-13033	all	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
74-4	13034-13041	centres	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
74-5	13042-13050	operated	_	_
74-6	13051-13054	MRI	_	_
74-7	13055-13063	machines	_	_
74-8	13064-13068	with	_	_
74-9	13069-13070	a	_	_
74-10	13071-13075	main	_	_
74-11	13076-13084	magnetic	_	_
74-12	13085-13090	field	_	_
74-13	13091-13093	of	_	_
74-14	13094-13095	3	_	_
74-15	13095-13096	 	_	_
74-16	13096-13097	T	_	_
74-17	13098-13099	(	_	_
74-18	13099-13100	T	_	_
74-19	13100-13101	)	_	_
74-20	13101-13102	.	_	_

75-1	13103-13110	Centres	_	_
75-2	13111-13113	in	_	_
75-3	13114-13120	London	_	_
75-4	13121-13124	and	_	_
75-5	13125-13134	Cambridge	_	_
75-6	13135-13143	operated	_	_
75-7	13144-13153	nominally	_	_
75-8	13154-13163	identical	_	_
75-9	13164-13165	3	_	_
75-10	13165-13166	 	_	_
75-11	13166-13167	T	_	_
75-12	13168-13175	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
75-13	13176-13179	Tim	_	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
75-14	13180-13184	Trio	_	_
75-15	13185-13192	systems	_	_
75-16	13193-13200	running	_	_
75-17	13201-13204	the	_	_
75-18	13205-13210	syngo	_	_
75-19	13211-13213	MR	_	_
75-20	13214-13217	B17	_	_
75-21	13218-13226	software	_	_
75-22	13227-13231	with	_	_
75-23	13232-13233	a	_	_
75-24	13234-13241	Siemens	_	_
75-25	13242-13244	32	_	_
75-26	13245-13252	channel	_	_
75-27	13253-13265	receive-only	_	_
75-28	13266-13278	phased-array	_	_
75-29	13279-13283	head	_	_
75-30	13284-13288	coil	_	_
75-31	13288-13289	.	_	_

76-1	13290-13293	The	_	_
76-2	13294-13304	Manchester	_	_
76-3	13305-13311	centre	_	_
76-4	13312-13320	operated	_	_
76-5	13321-13322	a	_	_
76-6	13323-13324	3	_	_
76-7	13324-13325	 	_	_
76-8	13325-13326	T	_	_
76-9	13327-13334	Philips	_	_
76-10	13335-13342	Achieva	_	_
76-11	13343-13350	running	_	_
76-12	13351-13358	version	_	_
76-13	13359-13366	2.6.3.5	_	_
76-14	13367-13375	software	_	_
76-15	13376-13379	and	_	_
76-16	13380-13382	an	_	_
76-17	13383-13384	8	_	_
76-18	13385-13392	element	_	_
76-19	13393-13398	SENSE	_	_
76-20	13399-13403	head	_	_
76-21	13404-13408	coil	_	_
76-22	13408-13409	.	_	_

77-1	13410-13413	For	_	_
77-2	13414-13424	anatomical	_	_
77-3	13425-13431	images	_	_
77-4	13431-13432	,	_	_
77-5	13433-13436	160	_	_
77-6	13437-13452	high-resolution	_	_
77-7	13453-13455	T1	_	_
77-8	13455-13456	-	_	_
77-9	13456-13464	weighted	_	_
77-10	13465-13473	anatomic	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
77-11	13474-13480	MPRAGE	_	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
77-12	13481-13486	axial	_	_
77-13	13487-13493	images	_	_
77-14	13494-13495	(	_	_
77-15	13495-13498	FOV	_	_
77-16	13499-13502	256	_	_
77-17	13502-13503	 	_	_
77-18	13503-13505	mm	_	_
77-19	13505-13506	,	_	_
77-20	13507-13516	thickness	_	_
77-21	13517-13520	1.0	_	_
77-22	13520-13521	 	_	_
77-23	13521-13523	mm	_	_
77-24	13523-13524	,	_	_
77-25	13525-13530	voxel	_	_
77-26	13531-13535	size	_	_
77-27	13536-13539	1.0	_	_
77-28	13539-13540	 	_	_
77-29	13540-13541	×	_	_
77-30	13541-13542	 	_	_
77-31	13542-13545	1.0	_	_
77-32	13545-13546	 	_	_
77-33	13546-13547	×	_	_
77-34	13547-13548	 	_	_
77-35	13548-13551	1.0	_	_
77-36	13551-13552	)	_	_
77-37	13553-13557	were	_	_
77-38	13558-13566	acquired	_	_
77-39	13567-13568	(	_	_
77-40	13568-13573	total	_	_
77-41	13574-13582	duration	_	_
77-42	13583-13586	303	_	_
77-43	13586-13587	 	_	_
77-44	13587-13588	s	_	_
77-45	13588-13589	)	_	_
77-46	13589-13590	.	_	_

78-1	13591-13601	Functional	_	_
78-2	13602-13606	data	_	_
78-3	13607-13611	were	_	_
78-4	13612-13620	acquired	_	_
78-5	13621-13626	using	_	_
78-6	13627-13628	a	_	_
78-7	13629-13631	T2	_	_
78-8	13631-13632	*	_	_
78-9	13633-13641	weighted	_	_
78-10	13642-13653	echo-planar	_	_
78-11	13654-13661	imaging	_	_
78-12	13662-13670	sequence	_	_
78-13	13671-13681	collecting	_	_
78-14	13682-13684	36	_	_
78-15	13685-13699	non-contiguous	_	_
78-16	13700-13701	(	_	_
78-17	13701-13703	0%	_	_
78-18	13704-13707	gap	_	_
78-19	13707-13708	)	_	_
78-20	13709-13712	3.0	_	_
78-21	13712-13713	 	_	_
78-22	13713-13715	mm	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#Thing
78-23	13716-13721	axial	_	_
78-24	13722-13728	slices	_	_
78-25	13729-13737	covering	_	_
78-26	13738-13741	the	_	_
78-27	13742-13748	entire	_	_
78-28	13749-13754	brain	_	_
78-29	13755-13756	(	_	_
78-30	13756-13758	TE	_	_
78-31	13758-13759	 	_	_
78-32	13759-13760	=	_	_
78-33	13760-13761	 	_	_
78-34	13761-13763	31	_	_
78-35	13763-13764	 	_	_
78-36	13764-13766	ms	_	_
78-37	13766-13767	,	_	_
78-38	13768-13770	TR	_	_
78-39	13770-13771	 	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	_
78-40	13771-13772	=	_	_
78-41	13772-13773	 	_	_
78-42	13773-13777	2000	_	_
78-43	13777-13778	 	_	_
78-44	13778-13780	ms	_	_
78-45	13780-13781	,	_	_
78-46	13782-13785	FOV	_	_
78-47	13786-13789	225	_	_
78-48	13789-13790	 	_	_
78-49	13790-13792	mm	_	_
78-50	13792-13793	,	_	_
78-51	13794-13796	64	_	_
78-52	13796-13797	 	_	_
78-53	13797-13798	×	_	_
78-54	13798-13799	 	_	_
78-55	13799-13801	64	_	_
78-56	13801-13802	 	_	_
78-57	13802-13804	mm	_	_
78-58	13805-13811	matrix	_	_
78-59	13812-13816	size	_	_
78-60	13817-13819	in	_	_
78-61	13820-13827	Fourier	_	_
78-62	13828-13833	space	_	_
78-63	13833-13834	)	_	_
78-64	13834-13835	.	_	_

79-1	13836-13840	Each	_	_
79-2	13841-13844	run	_	_
79-3	13845-13847	of	_	_
79-4	13848-13851	the	_	_
79-5	13852-13855	MID	_	_
79-6	13856-13860	task	_	_
79-7	13861-13869	produced	_	_
79-8	13870-13871	a	_	_
79-9	13872-13877	total	_	_
79-10	13878-13880	of	_	_
79-11	13881-13884	216	_	_
79-12	13885-13892	volumes	_	_
79-13	13893-13895	of	_	_
79-14	13896-13906	functional	_	_
79-15	13907-13910	MRI	_	_
79-16	13911-13915	data	_	_
79-17	13915-13916	.	_	_
79-18	13917-13921	fMRI	_	_
79-19	13922-13926	Data	_	_
79-20	13927-13935	analyses	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-21	13936-13940	Data	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-22	13941-13955	pre-processing	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-23	13956-13959	and	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-24	13960-13971	statistical	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-25	13972-13980	analysis	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-26	13981-13985	were	_	_
79-27	13986-13995	conducted	_	_
79-28	13996-14001	using	_	_
79-29	14002-14006	FEAT	_	_
79-30	14007-14008	(	_	_
79-31	14008-14012	fMRI	_	_
79-32	14013-14019	Expert	_	_
79-33	14020-14028	Analysis	_	_
79-34	14029-14033	Tool	_	_
79-35	14033-14034	)	_	_
79-36	14035-14039	from	_	_
79-37	14040-14043	the	_	_
79-38	14044-14049	FMRIB	_	_
79-39	14050-14058	Software	_	_
79-40	14059-14066	Library	_	_
79-41	14067-14068	(	_	_
79-42	14068-14086	www.fmrib.ox.ac.uk	_	_
79-43	14086-14087	/	_	_
79-44	14087-14090	fsl	_	_
79-45	14090-14091	)	_	_
79-46	14091-14092	.	_	_

80-1	14093-14108	Pre-statistical	_	_
80-2	14109-14119	processing	_	_
80-3	14120-14123	was	_	_
80-4	14124-14126	as	_	_
80-5	14127-14134	follows	_	_
80-6	14134-14135	:	_	_
80-7	14136-14142	motion	_	_
80-8	14143-14153	correction	_	_
80-9	14154-14163	utilizing	_	_
80-10	14164-14169	FMRIB	_	_
80-11	14169-14170	’	_	_
80-12	14170-14171	s	_	_
80-13	14172-14178	Linear	_	_
80-14	14179-14184	Image	_	_
80-15	14185-14197	Registration	_	_
80-16	14198-14202	Tool	_	_
80-17	14203-14204	(	_	_
80-18	14204-14211	MCFLIRT	_	_
80-19	14211-14212	;	_	_
80-20	14213-14222	non-brain	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
80-21	14223-14229	matter	_	_
80-22	14230-14237	removal	_	_
80-23	14238-14243	using	_	_
80-24	14244-14249	Brain	_	_
80-25	14250-14260	Extraction	_	_
80-26	14261-14265	Tool	_	_
80-27	14266-14267	(	_	_
80-28	14267-14270	BET	_	_
80-29	14270-14271	)	_	_
80-30	14271-14272	;	_	_
80-31	14273-14280	spatial	_	_
80-32	14281-14290	smoothing	_	_
80-33	14291-14295	with	_	_
80-34	14296-14297	a	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
80-35	14298-14299	5	_	_
80-36	14299-14300	-	_	_
80-37	14300-14302	mm	_	_
80-38	14303-14313	full-width	_	_
80-39	14314-14318	half	_	_
80-40	14319-14326	maximum	_	_
80-41	14327-14335	Gaussian	_	_
80-42	14336-14342	kernel	_	_
80-43	14342-14343	;	_	_
80-44	14344-14354	mean-based	_	_
80-45	14355-14364	intensity	_	_
80-46	14365-14378	normalization	_	_
80-47	14378-14379	;	_	_
80-48	14380-14389	nonlinear	_	_
80-49	14390-14399	high-pass	_	_
80-50	14400-14408	temporal	_	_
80-51	14409-14418	filtering	_	_
80-52	14419-14420	(	_	_
80-53	14420-14437	Gaussian-weighted	_	_
80-54	14438-14443	least	_	_
80-55	14444-14451	squares	_	_
80-56	14452-14460	straight	_	_
80-57	14461-14465	line	_	_
80-58	14466-14469	fit	_	_
80-59	14469-14470	,	_	_
80-60	14471-14475	with	_	_
80-61	14476-14481	sigma	_	_
80-62	14481-14482	 	_	_
80-63	14482-14483	=	_	_
80-64	14483-14484	 	_	_
80-65	14484-14488	25.0	_	_
80-66	14488-14489	 	_	_
80-67	14489-14490	s	_	_
80-68	14490-14491	)	_	_
80-69	14491-14492	.	_	_

81-1	14493-14496	The	_	_
81-2	14497-14500	six	_	_
81-3	14501-14506	rigid	_	_
81-4	14507-14511	body	_	_
81-5	14512-14520	movement	_	_
81-6	14521-14531	parameters	_	_
81-7	14532-14536	were	_	_
81-8	14537-14541	also	_	_
81-9	14542-14550	included	_	_
81-10	14551-14553	as	_	_
81-11	14554-14564	regressors	_	_
81-12	14565-14567	in	_	_
81-13	14568-14571	the	_	_
81-14	14572-14577	model	_	_
81-15	14578-14580	in	_	_
81-16	14581-14584	FSL	_	_
81-17	14585-14589	FEAT	_	_
81-18	14589-14590	.	_	_

82-1	14591-14594	For	_	_
82-2	14595-14599	each	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-3	14600-14611	participant	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-4	14611-14612	,	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-5	14613-14618	first	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-6	14619-14624	level	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-7	14625-14636	whole-brain	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-8	14637-14650	mixed-effects	_	_
82-9	14651-14659	analyses	_	_
82-10	14660-14664	were	_	_
82-11	14665-14674	performed	_	_
82-12	14675-14677	by	_	_
82-13	14678-14687	modelling	_	_
82-14	14688-14691	the	_	_
82-15	14692-14695	MID	_	_
82-16	14696-14708	anticipation	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
82-17	14709-14716	periods	_	_
82-18	14717-14718	(	_	_
82-19	14718-14721	i.e	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
82-20	14721-14722	.	_	_
82-21	14723-14727	gain	_	_
82-22	14727-14728	,	_	_
82-23	14729-14736	neutral	_	_
82-24	14736-14737	)	_	_
82-25	14738-14740	as	_	_
82-26	14741-14752	explanatory	_	_
82-27	14753-14762	variables	_	_
82-28	14763-14769	within	_	_
82-29	14770-14773	the	_	_
82-30	14774-14781	context	_	_
82-31	14782-14784	of	_	_
82-32	14785-14788	the	_	_
82-33	14789-14796	general	_	_
82-34	14797-14803	linear	_	_
82-35	14804-14809	model	_	_
82-36	14810-14812	on	_	_
82-37	14813-14814	a	_	_
82-38	14815-14829	voxel-by-voxel	_	_
82-39	14830-14835	basis	_	_
82-40	14836-14837	(	_	_
82-41	14837-14845	variable	_	_
82-42	14846-14852	boxcar	_	_
82-43	14853-14862	functions	_	_
82-44	14863-14866	for	_	_
82-45	14867-14870	the	_	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
82-46	14871-14874	cue	_	_
82-47	14874-14875	 	_	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
82-48	14875-14876	+	_	_
82-49	14876-14877	 	_	_
82-50	14877-14885	variable	_	_
82-51	14886-14898	anticipation	_	_
82-52	14899-14905	period	_	_
82-53	14906-14916	regressors	_	_
82-54	14917-14921	were	_	_
82-55	14922-14931	convolved	_	_
82-56	14932-14936	with	_	_
82-57	14937-14940	the	_	_
82-58	14941-14953	haemodynamic	_	_
82-59	14954-14962	response	_	_
82-60	14963-14971	function	_	_
82-61	14971-14972	)	_	_
82-62	14972-14973	.	_	_

83-1	14974-14977	The	_	_
83-2	14978-14982	gain	_	_
83-3	14983-14986	and	_	_
83-4	14987-14994	neutral	_	_
83-5	14995-15002	outcome	_	_
83-6	15003-15010	periods	_	_
83-7	15011-15012	(	_	_
83-8	15012-15013	“	_	_
83-9	15013-15016	Hit	_	_
83-10	15016-15017	”	_	_
83-11	15018-15021	and	_	_
83-12	15022-15023	“	_	_
83-13	15023-15027	Miss	_	_
83-14	15027-15028	”	_	_
83-15	15028-15029	)	_	_
83-16	15030-15034	were	_	_
83-17	15035-15044	regressed	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-18	15045-15048	out	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-19	15049-15051	of	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-20	15052-15055	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-21	15056-15066	functional	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-22	15067-15071	time	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-23	15072-15078	series	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-24	15079-15081	as	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-25	15082-15092	conditions	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-26	15093-15095	of	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-27	15096-15098	no	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-28	15099-15107	interest	_	_
83-29	15108-15111	for	_	_
83-30	15112-15115	the	_	_
83-31	15116-15124	analyses	_	_
83-32	15125-15133	reported	_	_
83-33	15134-15138	here	_	_
83-34	15138-15139	.	_	_

84-1	15140-15146	During	_	_
84-2	15147-15152	these	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
84-3	15153-15158	first	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
84-4	15159-15164	level	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
84-5	15165-15173	analyses	_	_
84-6	15173-15174	,	_	_
84-7	15175-15178	the	_	_
84-8	15179-15183	gain	_	_
84-9	15184-15196	anticipation	_	_
84-10	15196-15197	 	_	_
84-11	15197-15198	>	_	_
84-12	15198-15199	 	_	_
84-13	15199-15206	neutral	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
84-14	15207-15219	anticipation	_	_
84-15	15220-15228	contrast	_	_
84-16	15229-15232	was	_	_
84-17	15233-15243	formulated	_	_
84-18	15243-15244	.	_	_

85-1	15245-15250	Owing	_	_
85-2	15251-15253	to	_	_
85-3	15254-15257	the	_	_
85-4	15258-15263	small	_	_
85-5	15264-15270	number	_	_
85-6	15271-15273	of	_	_
85-7	15274-15278	loss	_	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
85-8	15279-15285	trials	_	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
85-9	15286-15288	in	_	_
85-10	15289-15292	the	_	_
85-11	15293-15300	current	_	_
85-12	15301-15305	task	_	_
85-13	15305-15306	,	_	_
85-14	15307-15310	the	_	_
85-15	15311-15315	lose	_	_
85-16	15316-15319	cue	_	_
85-17	15319-15320	 	_	_
85-18	15320-15321	+	_	_
85-19	15321-15322	 	_	_
85-20	15322-15334	anticipation	_	_
85-21	15335-15338	and	_	_
85-22	15339-15346	outcome	_	_
85-23	15347-15354	periods	_	_
85-24	15355-15356	(	_	_
85-25	15356-15357	“	_	_
85-26	15357-15360	Hit	_	_
85-27	15360-15361	”	_	_
85-28	15362-15365	and	_	_
85-29	15366-15367	“	_	_
85-30	15367-15371	Miss	_	_
85-31	15371-15372	”	_	_
85-32	15372-15373	)	_	_
85-33	15374-15378	were	_	_
85-34	15379-15391	additionally	_	_
85-35	15392-15401	regressed	_	_
85-36	15402-15405	out	_	_
85-37	15406-15408	of	_	_
85-38	15409-15412	the	_	_
85-39	15413-15423	functional	_	_
85-40	15424-15428	time	_	_
85-41	15429-15435	series	_	_
85-42	15436-15438	as	_	_
85-43	15439-15449	conditions	_	_
85-44	15450-15452	of	_	_
85-45	15453-15455	no	_	_
85-46	15456-15464	interest	_	_
85-47	15464-15465	.	_	_

86-1	15466-15475	Therefore	_	_
86-2	15475-15476	,	_	_
86-3	15477-15480	the	_	_
86-4	15481-15486	fewer	_	_
86-5	15487-15493	number	_	_
86-6	15494-15496	of	_	_
86-7	15497-15501	lose	_	_
86-8	15502-15508	trials	_	_
86-9	15509-15511	on	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
86-10	15512-15515	the	_	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
86-11	15516-15519	MID	_	_
86-12	15520-15524	task	_	_
86-13	15525-15530	meant	_	_
86-14	15531-15533	we	_	_
86-15	15534-15538	were	_	_
86-16	15539-15545	unable	_	_
86-17	15546-15548	to	_	_
86-18	15549-15556	examine	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
86-19	15557-15567	voxel-wise	_	_
86-20	15568-15573	group	_	_
86-21	15574-15585	differences	_	_
86-22	15586-15588	in	_	_
86-23	15589-15593	loss	_	_
86-24	15594-15606	anticipation	_	_
86-25	15606-15607	.	_	_

87-1	15608-15611	The	_	_
87-2	15612-15615	end	_	_
87-3	15616-15624	fixation	_	_
87-4	15625-15631	period	_	_
87-5	15632-15634	of	_	_
87-6	15635-15638	the	_	_
87-7	15639-15643	task	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
87-8	15644-15650	served	_	_
87-9	15651-15653	as	_	_
87-10	15654-15657	the	_	_
87-11	15658-15666	implicit	_	_
87-12	15667-15675	baseline	_	_
87-13	15675-15676	.	_	_

88-1	15677-15689	Registration	_	_
88-2	15690-15693	was	_	_
88-3	15694-15703	conducted	_	_
88-4	15704-15711	through	_	_
88-5	15712-15713	a	_	_
88-6	15714-15722	two-step	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
88-7	15723-15732	procedure	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
88-8	15732-15733	,	_	_
88-9	15734-15741	whereby	_	_
88-10	15742-15745	EPI	_	_
88-11	15746-15752	images	_	_
88-12	15753-15757	were	_	_
88-13	15758-15763	first	_	_
88-14	15764-15774	registered	_	_
88-15	15775-15777	to	_	_
88-16	15778-15781	the	_	_
88-17	15782-15797	high-resolution	_	_
88-18	15798-15800	T1	_	_
88-19	15801-15811	structural	_	_
88-20	15812-15817	image	_	_
88-21	15817-15818	,	_	_
88-22	15819-15823	then	_	_
88-23	15824-15828	into	_	_
88-24	15829-15837	standard	_	_
88-25	15838-15839	(	_	_
88-26	15839-15847	Montreal	_	_
88-27	15848-15860	Neurological	_	_
88-28	15861-15870	Institute	_	_
88-29	15870-15871	,	_	_
88-30	15872-15875	MNI	_	_
88-31	15876-15882	avg152	_	_
88-32	15883-15891	template	_	_
88-33	15891-15892	)	_	_
88-34	15893-15898	space	_	_
88-35	15898-15899	,	_	_
88-36	15900-15904	with	_	_
88-37	15905-15907	12	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
88-38	15907-15908	-	_	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
88-39	15908-15917	parameter	_	_
88-40	15918-15924	affine	_	_
88-41	15925-15940	transformations	_	_
88-42	15940-15941	.	_	_

89-1	15942-15954	Higher-level	_	_
89-2	15955-15956	(	_	_
89-3	15956-15962	within	_	_
89-4	15963-15968	group	_	_
89-5	15969-15979	one-sample	_	_
89-6	15980-15987	t-tests	_	_
89-7	15988-15991	and	_	_
89-8	15992-16005	between-group	_	_
89-9	16006-16017	independent	_	_
89-10	16018-16025	samples	_	_
89-11	16026-16033	t-tests	_	_
89-12	16033-16034	)	_	_
89-13	16035-16039	were	_	_
89-14	16040-16049	conducted	_	_
89-15	16050-16052	on	_	_
89-16	16053-16056	the	_	_
89-17	16057-16061	gain	_	_
89-18	16062-16074	anticipation	_	_
89-19	16074-16075	 	_	_
89-20	16075-16076	>	_	_
89-21	16076-16077	 	_	_
89-22	16077-16084	neutral	_	_
89-23	16085-16097	anticipation	_	_
89-24	16098-16106	contrast	_	_
89-25	16107-16112	using	_	_
89-26	16113-16116	the	_	_
89-27	16117-16126	randomise	_	_
89-28	16127-16136	programme	_	_
89-29	16137-16139	in	_	_
89-30	16140-16143	FSL	_	_
89-31	16143-16144	.	_	_

90-1	16145-16154	Randomise	_	_
90-2	16155-16162	employs	_	_
90-3	16163-16164	a	_	_
90-4	16165-16176	permutation	_	_
90-5	16177-16185	approach	_	_
90-6	16186-16193	through	_	_
90-7	16194-16204	resampling	_	_
90-8	16204-16205	.	_	_

91-1	16206-16218	Significance	_	_
91-2	16219-16220	(	_	_
91-3	16220-16224	PFWE	_	_
91-4	16224-16225	 	_	_
91-5	16225-16226	<	_	_
91-6	16226-16227	 	_	_
91-7	16227-16231	0.05	_	_
91-8	16231-16232	)	_	_
91-9	16233-16236	for	_	_
91-10	16237-16240	the	_	_
91-11	16241-16245	gain	_	_
91-12	16246-16258	anticipation	_	_
91-13	16258-16259	 	_	_
91-14	16259-16260	>	_	_
91-15	16260-16261	 	_	_
91-16	16261-16268	neutral	_	_
91-17	16269-16281	anticipation	_	_
91-18	16282-16290	contrast	_	_
91-19	16291-16293	on	_	_
91-20	16294-16298	both	_	_
91-21	16299-16302	the	_	_
91-22	16303-16313	one-sample	_	_
91-23	16314-16317	and	_	_
91-24	16318-16329	independent	_	_
91-25	16330-16337	samples	_	_
91-26	16338-16345	t-tests	_	_
91-27	16346-16349	was	_	_
91-28	16350-16359	conducted	_	_
91-29	16360-16366	taking	_	_
91-30	16367-16368	a	_	_
91-31	16369-16383	threshold-free	_	_
91-32	16384-16391	cluster	_	_
91-33	16392-16403	enhancement	_	_
91-34	16404-16405	(	_	_
91-35	16405-16409	TFCE	_	_
91-36	16409-16410	)	_	_
91-37	16411-16419	approach	_	_
91-38	16420-16423	and	_	_
91-39	16424-16429	using	_	_
91-40	16430-16434	5000	_	_
91-41	16435-16447	permutations	_	_
91-42	16447-16448	.	_	_

92-1	16449-16453	TFCE	_	_
92-2	16454-16458	aims	_	_
92-3	16459-16461	to	_	_
92-4	16462-16470	maintain	_	_
92-5	16471-16474	the	_	_
92-6	16475-16486	sensitivity	_	_
92-7	16487-16489	of	_	_
92-8	16490-16503	cluster-based	_	_
92-9	16504-16516	thresholding	_	_
92-10	16516-16517	,	_	_
92-11	16518-16523	while	_	_
92-12	16524-16532	avoiding	_	_
92-13	16533-16536	the	_	_
92-14	16537-16546	arbitrary	_	_
92-15	16547-16553	nature	_	_
92-16	16554-16556	of	_	_
92-17	16557-16566	threshold	_	_
92-18	16567-16573	choice	_	_
92-19	16573-16574	.	_	_

93-1	16575-16580	Given	_	_
93-2	16581-16584	the	_	_
93-3	16585-16596	differences	_	_
93-4	16597-16599	in	_	_
93-5	16600-16608	scanners	_	_
93-6	16609-16615	across	_	_
93-7	16616-16619	the	_	_
93-8	16620-16625	three	_	_
93-9	16626-16631	sites	_	_
93-10	16631-16632	,	_	_
93-11	16633-16638	these	_	_
93-12	16639-16647	analyses	_	_
93-13	16648-16652	were	_	_
93-14	16653-16662	conducted	_	_
93-15	16663-16668	while	_	_
93-16	16669-16673	also	_	_
93-17	16674-16685	controlling	_	_
93-18	16686-16689	for	_	_
93-19	16690-16695	study	_	_
93-20	16696-16700	site	_	_
93-21	16700-16701	.	_	_

94-1	16702-16712	Trial-Wise	_	_
94-2	16713-16717	beta	_	_
94-3	16718-16723	value	_	_
94-4	16724-16729	image	_	_
94-5	16730-16738	analyses	_	_
94-6	16739-16743	Data	_	_
94-7	16744-16758	pre-processing	_	_
94-8	16759-16762	was	_	_
94-9	16763-16767	also	_	_
94-10	16768-16777	initially	_	_
94-11	16778-16787	conducted	_	_
94-12	16788-16793	using	_	_
94-13	16794-16798	FEAT	_	_
94-14	16799-16800	(	_	_
94-15	16800-16804	fMRI	_	_
94-16	16805-16811	Expert	_	_
94-17	16812-16820	Analysis	_	_
94-18	16821-16825	Tool	_	_
94-19	16825-16826	)	_	_
94-20	16827-16831	from	_	_
94-21	16832-16835	the	_	_
94-22	16836-16841	FMRIB	_	_
94-23	16842-16850	Software	_	_
94-24	16851-16858	Library	_	_
94-25	16859-16860	(	_	_
94-26	16860-16878	www.fmrib.ox.ac.uk	_	_
94-27	16878-16879	/	_	_
94-28	16879-16882	fsl	_	_
94-29	16882-16883	)	_	_
94-30	16884-16886	as	_	_
94-31	16887-16896	described	_	_
94-32	16897-16902	above	_	_
94-33	16902-16903	.	_	_

95-1	16904-16907	For	_	_
95-2	16908-16912	each	_	_
95-3	16913-16924	participant	_	_
95-4	16924-16925	,	_	_
95-5	16926-16930	each	_	_
95-6	16931-16941	individual	_	_
95-7	16942-16946	gain	_	_
95-8	16947-16950	and	_	_
95-9	16951-16958	neutral	_	_
95-10	16959-16971	anticipation	_	_
95-11	16972-16977	epoch	_	_
95-12	16978-16979	(	_	_
95-13	16979-16982	cue	_	_
95-14	16982-16983	 	_	_
95-15	16983-16984	+	_	_
95-16	16984-16985	 	_	_
95-17	16985-16993	variable	_	_
95-18	16994-17006	anticipation	_	_
95-19	17007-17013	period	_	_
95-20	17013-17014	)	_	_
95-21	17015-17018	was	_	_
95-22	17019-17029	separately	_	_
95-23	17030-17038	modelled	_	_
95-24	17039-17045	within	_	_
95-25	17046-17049	the	_	_
95-26	17050-17057	context	_	_
95-27	17058-17060	of	_	_
95-28	17061-17064	the	_	_
95-29	17065-17072	general	_	_
95-30	17073-17079	linear	_	_
95-31	17080-17085	model	_	_
95-32	17085-17086	.	_	_

96-1	17087-17091	This	_	_
96-2	17092-17100	approach	_	_
96-3	17101-17108	yielded	_	_
96-4	17109-17110	a	_	_
96-5	17111-17116	total	_	_
96-6	17117-17119	of	_	_
96-7	17120-17122	18	_	_
96-8	17123-17129	unique	_	_
96-9	17130-17134	beta	_	_
96-10	17135-17140	value	_	_
96-11	17141-17147	images	_	_
96-12	17148-17151	for	_	_
96-13	17152-17156	each	_	_
96-14	17157-17159	of	_	_
96-15	17160-17163	the	_	_
96-16	17164-17168	gain	_	_
96-17	17169-17172	and	_	_
96-18	17173-17180	neutral	_	_
96-19	17181-17193	anticipation	_	_
96-20	17194-17204	conditions	_	_
96-21	17205-17207	on	_	_
96-22	17208-17212	each	_	_
96-23	17213-17216	run	_	_
96-24	17217-17219	of	_	_
96-25	17220-17223	the	_	_
96-26	17224-17227	MID	_	_
96-27	17228-17232	task	_	_
96-28	17232-17233	.	_	_

97-1	17234-17238	This	_	_
97-2	17239-17244	meant	_	_
97-3	17245-17249	that	_	_
97-4	17250-17254	each	_	_
97-5	17255-17265	voxel-wise	_	_
97-6	17266-17270	beta	_	_
97-7	17271-17276	value	_	_
97-8	17277-17282	image	_	_
97-9	17283-17292	reflected	_	_
97-10	17293-17296	the	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
97-11	17297-17306	magnitude	_	_
97-12	17307-17309	of	_	_
97-13	17310-17313	the	_	_
97-14	17314-17325	hemodynamic	_	_
97-15	17326-17334	response	_	_
97-16	17335-17341	evoked	_	_
97-17	17342-17344	by	_	_
97-18	17345-17349	each	_	_
97-19	17350-17352	of	_	_
97-20	17353-17356	the	_	_
97-21	17357-17361	gain	_	_
97-22	17362-17365	and	_	_
97-23	17366-17373	neutral	_	_
97-24	17374-17386	anticipation	_	_
97-25	17387-17393	epochs	_	_
97-26	17393-17394	.	_	_

98-1	17395-17399	Each	_	_
98-2	17400-17404	beta	_	_
98-3	17405-17410	value	_	_
98-4	17411-17416	image	_	_
98-5	17417-17420	for	_	_
98-6	17421-17425	each	_	_
98-7	17426-17429	MID	_	_
98-8	17430-17433	run	_	_
98-9	17434-17437	was	_	_
98-10	17438-17442	then	_	_
98-11	17443-17455	subsequently	_	_
98-12	17456-17466	registered	_	_
98-13	17467-17471	into	_	_
98-14	17472-17480	standard	_	_
98-15	17481-17482	(	_	_
98-16	17482-17485	MNI	_	_
98-17	17486-17492	avg152	_	_
98-18	17493-17501	template	_	_
98-19	17501-17502	)	_	_
98-20	17503-17508	space	_	_
98-21	17509-17515	before	_	_
98-22	17516-17521	being	_	_
98-23	17522-17534	concatenated	_	_
98-24	17535-17537	to	_	_
98-25	17538-17546	generate	_	_
98-26	17547-17548	a	_	_
98-27	17549-17553	beta	_	_
98-28	17554-17559	value	_	_
98-29	17560-17561	“	_	_
98-30	17561-17571	trial-wise	_	_
98-31	17571-17572	”	_	_
98-32	17573-17574	(	_	_
98-33	17574-17577	e.g	_	_
98-34	17577-17578	.	_	_
98-35	17578-17579	,	_	_
98-36	17580-17584	gain	_	_
98-37	17585-17597	anticipation	_	_
98-38	17597-17598	)	_	_
98-39	17599-17603	time	_	_
98-40	17604-17610	series	_	_
98-41	17610-17611	.	_	_

99-1	17612-17616	Each	_	_
99-2	17617-17621	beta	_	_
99-3	17622-17627	value	_	_
99-4	17628-17638	trial-wise	_	_
99-5	17639-17643	time	_	_
99-6	17644-17650	series	_	_
99-7	17651-17654	for	_	_
99-8	17655-17659	each	_	_
99-9	17660-17663	MID	_	_
99-10	17664-17667	run	_	_
99-11	17668-17671	was	_	_
99-12	17672-17679	further	_	_
99-13	17680-17692	concatenated	_	_
99-14	17693-17699	across	_	_
99-15	17700-17704	runs	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
99-16	17705-17707	to	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
99-17	17708-17716	generate	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
99-18	17717-17718	a	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
99-19	17719-17725	single	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
99-20	17726-17730	beta	_	_
99-21	17731-17736	value	_	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
99-22	17737-17747	trial-wise	_	_
99-23	17748-17752	time	_	_
99-24	17753-17759	series	_	_
99-25	17760-17763	for	_	_
99-26	17764-17767	the	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-27	17768-17772	gain	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-28	17773-17776	and	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-29	17777-17784	neutral	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-30	17785-17788	MID	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-31	17789-17801	anticipation	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-32	17802-17812	conditions	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-33	17812-17813	.	_	_

100-1	17814-17818	This	_	_
100-2	17819-17828	procedure	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#Thing
100-3	17829-17836	yielded	_	_
100-4	17837-17838	a	_	_
100-5	17839-17849	thirty-six	_	_
100-6	17850-17854	beta	_	_
100-7	17855-17860	value	_	_
100-8	17861-17871	trial-wise	_	_
100-9	17872-17876	time	_	_
100-10	17877-17883	series	_	_
100-11	17884-17889	image	_	_
100-12	17890-17893	for	_	_
100-13	17894-17898	each	_	_
100-14	17899-17910	participant	_	_
100-15	17911-17914	for	_	_
100-16	17915-17918	the	_	_
100-17	17919-17923	gain	_	_
100-18	17924-17927	and	_	_
100-19	17928-17935	neutral	_	_
100-20	17936-17948	anticipation	_	_
100-21	17949-17959	conditions	_	_
100-22	17959-17960	.	_	_

101-1	17961-17964	The	_	_
101-2	17965-17972	neutral	_	_
101-3	17973-17983	trial-wise	_	_
101-4	17984-17988	time	_	_
101-5	17989-17995	series	_	_
101-6	17996-17999	was	_	_
101-7	18000-18004	then	_	_
101-8	18005-18011	simply	_	_
101-9	18012-18022	subtracted	_	_
101-10	18023-18027	from	_	_
101-11	18028-18031	the	_	_
101-12	18032-18036	gain	_	_
101-13	18037-18047	trial-wise	_	_
101-14	18048-18052	time	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-15	18053-18059	series	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-16	18060-18062	to	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-17	18063-18068	yield	_	_
101-18	18069-18070	a	_	_
101-19	18071-18075	gain	_	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
101-20	18076-18088	anticipation	_	_
101-21	18088-18089	 	_	_
101-22	18089-18090	>	_	_
101-23	18090-18091	 	_	_
101-24	18091-18098	neutral	_	_
101-25	18099-18111	anticipation	_	_
101-26	18112-18120	contrast	_	_
101-27	18121-18125	time	_	_
101-28	18126-18132	series	_	_
101-29	18133-18134	(	_	_
101-30	18134-18137	see	_	_
101-31	18138-18151	Supplementary	_	_
101-32	18152-18155	Fig	_	_
101-33	18155-18156	.	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-34	18157-18158	1	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-35	18158-18159	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-36	18159-18160	.	_	_

102-1	18161-18165	This	_	_
102-2	18166-18170	beta	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
102-3	18171-18176	value	_	_
102-4	18177-18187	trial-wise	_	_
102-5	18188-18192	time	_	_
102-6	18193-18199	series	_	_
102-7	18200-18206	method	_	_
102-8	18207-18210	has	_	_
102-9	18211-18215	been	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
102-10	18216-18226	previously	_	_
102-11	18227-18231	used	_	_
102-12	18232-18234	to	_	_
102-13	18235-18242	examine	_	_
102-14	18243-18255	connectivity	_	_
102-15	18256-18262	during	_	_
102-16	18263-18272	cognitive	_	_
102-17	18273-18278	tasks	_	_
102-18	18278-18279	,	_	_
102-19	18280-18289	including	_	_
102-20	18290-18293	the	_	_
102-21	18294-18297	MID	_	_
102-22	18298-18302	task	_	_
102-23	18302-18303	.	_	_

103-1	18304-18307	The	_	_
103-2	18308-18313	small	_	_
103-3	18313-18314	,	_	_
103-4	18315-18323	variable	_	_
103-5	18324-18325	(	_	_
103-6	18325-18346	performance-dependent	_	_
103-7	18346-18347	)	_	_
103-8	18348-18354	number	_	_
103-9	18355-18357	of	_	_
103-10	18358-18364	events	_	_
103-11	18365-18368	for	_	_
103-12	18369-18372	the	_	_
103-13	18373-18380	outcome	_	_
103-14	18381-18388	periods	_	_
103-15	18389-18390	(	_	_
103-16	18390-18391	“	_	_
103-17	18391-18395	hits	_	_
103-18	18395-18396	”	_	_
103-19	18397-18400	and	_	_
103-20	18401-18402	“	_	_
103-21	18402-18408	misses	_	_
103-22	18408-18409	”	_	_
103-23	18409-18410	)	_	_
103-24	18410-18411	,	_	_
103-25	18412-18415	and	_	_
103-26	18416-18419	the	_	_
103-27	18420-18425	small	_	_
103-28	18426-18432	number	_	_
103-29	18433-18435	of	_	_
103-30	18436-18440	loss	_	_
103-31	18441-18447	trials	_	_
103-32	18448-18450	in	_	_
103-33	18451-18454	the	_	_
103-34	18455-18459	task	_	_
103-35	18459-18460	,	_	_
103-36	18461-18466	meant	_	_
103-37	18467-18471	that	_	_
103-38	18472-18474	we	_	_
103-39	18475-18480	could	_	_
103-40	18481-18484	not	_	_
103-41	18485-18493	generate	_	_
103-42	18494-18504	trial-wise	_	_
103-43	18505-18509	beta	_	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
103-44	18510-18515	value	_	_
103-45	18516-18522	images	_	_
103-46	18523-18526	for	_	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
103-47	18527-18532	these	_	_
103-48	18533-18539	events	_	_
103-49	18539-18540	.	_	_

104-1	18541-18550	Therefore	_	_
104-2	18550-18551	,	_	_
104-3	18552-18556	gain	_	_
104-4	18557-18560	and	_	_
104-5	18561-18568	neutral	_	_
104-6	18569-18576	outcome	_	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
104-7	18577-18578	(	_	_
104-8	18578-18582	well	_	_
104-9	18583-18585	as	_	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
104-10	18586-18590	lose	_	_
104-11	18591-18603	anticipation	_	_
104-12	18604-18607	and	_	_
104-13	18608-18615	outcome	_	_
104-14	18615-18616	)	_	_
104-15	18617-18623	events	_	_
104-16	18624-18628	were	_	_
104-17	18629-18638	regressed	_	_
104-18	18639-18642	out	_	_
104-19	18643-18645	of	_	_
104-20	18646-18649	the	_	_
104-21	18650-18660	functional	_	_
104-22	18661-18665	time	_	_
104-23	18666-18672	series	_	_
104-24	18673-18675	as	_	_
104-25	18676-18686	conditions	_	_
104-26	18687-18689	of	_	_
104-27	18690-18692	no	_	_
104-28	18693-18701	interest	_	_
104-29	18702-18708	during	_	_
104-30	18709-18712	the	_	_
104-31	18713-18718	first	_	http://maven.renci.org/NeuroBridge/neurobridge#Age
104-32	18719-18724	level	_	_
104-33	18725-18733	analyses	_	_
104-34	18733-18734	.	_	_

105-1	18735-18739	This	_	_
105-2	18740-18745	meant	_	_
105-3	18746-18750	that	_	_
105-4	18751-18754	the	_	_
105-5	18755-18759	same	_	_
105-6	18760-18763	end	_	_
105-7	18764-18772	fixation	_	_
105-8	18773-18779	period	_	_
105-9	18780-18782	of	_	_
105-10	18783-18786	the	_	_
105-11	18787-18791	task	_	_
105-12	18792-18796	also	_	_
105-13	18797-18803	served	_	_
105-14	18804-18806	as	_	_
105-15	18807-18810	the	_	_
105-16	18811-18819	implicit	_	_
105-17	18820-18828	baseline	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
105-18	18829-18832	for	_	_
105-19	18833-18838	these	_	_
105-20	18839-18847	analyses	_	_
105-21	18847-18848	.	_	_

106-1	18849-18853	Time	_	_
106-2	18854-18860	series	_	_
106-3	18861-18871	Extraction	_	_
106-4	18872-18875	and	_	_
106-5	18876-18887	correlation	_	_
106-6	18888-18896	matrices	_	_
106-7	18897-18902	Using	_	_
106-8	18903-18906	the	_	_
106-9	18907-18921	Harvard-Oxford	_	_
106-10	18922-18927	atlas	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
106-11	18928-18929	(	_	_
106-12	18929-18931	96	_	_
106-13	18932-18940	cortical	_	_
106-14	18941-18944	and	_	_
106-15	18945-18947	14	_	_
106-16	18948-18959	subcortical	_	_
106-17	18960-18965	nodes	_	_
106-18	18965-18966	/	_	_
106-19	18966-18973	regions	_	_
106-20	18973-18974	)	_	_
106-21	18975-18977	as	_	_
106-22	18978-18981	our	_	_
106-23	18982-18992	connectome	_	_
106-24	18993-18995	of	_	_
106-25	18996-19004	interest	_	_
106-26	19004-19005	,	_	_
106-27	19006-19008	we	_	_
106-28	19009-19013	used	_	_
106-29	19014-19017	the	_	_
106-30	19018-19027	fslmeants	_	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
106-31	19028-19037	programme	_	_
106-32	19038-19040	to	_	_
106-33	19041-19048	extract	_	_
106-34	19049-19052	the	_	_
106-35	19053-19057	mean	_	_
106-36	19058-19062	beta	_	_
106-37	19063-19068	value	_	_
106-38	19069-19073	time	_	_
106-39	19074-19080	series	_	_
106-40	19081-19085	from	_	_
106-41	19086-19090	each	_	_
106-42	19091-19093	of	_	_
106-43	19094-19097	110	_	_
106-44	19098-19108	anatomical	_	_
106-45	19109-19116	regions	_	_
106-46	19117-19119	of	_	_
106-47	19120-19128	interest	_	_
106-48	19129-19130	(	_	_
106-49	19130-19133	ROI	_	_
106-50	19133-19134	)	_	_
106-51	19135-19138	for	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
106-52	19139-19142	the	_	_
106-53	19143-19147	gain	_	_
106-54	19148-19160	anticipation	_	_
106-55	19160-19161	 	_	_
106-56	19161-19162	>	_	_
106-57	19162-19163	 	_	_
106-58	19163-19170	neutral	_	_
106-59	19171-19179	contrast	_	_
106-60	19180-19184	beta	_	_
106-61	19185-19190	image	_	_
106-62	19191-19194	for	_	_
106-63	19195-19199	each	_	_
106-64	19200-19211	participant	_	_
106-65	19211-19212	.	_	_

107-1	19213-19218	Using	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
107-2	19219-19224	these	_	_
107-3	19225-19229	mean	_	_
107-4	19230-19233	ROI	_	_
107-5	19234-19238	time	_	_
107-6	19239-19245	series	_	_
107-7	19246-19253	outputs	_	_
107-8	19253-19254	,	_	_
107-9	19255-19257	we	_	_
107-10	19258-19262	then	_	_
107-11	19263-19272	conducted	_	_
107-12	19273-19280	Pearson	_	_
107-13	19281-19292	correlation	_	_
107-14	19293-19304	coefficient	_	_
107-15	19305-19313	analyses	_	_
107-16	19314-19316	to	_	_
107-17	19317-19326	construct	_	_
107-18	19327-19332	whole	_	_
107-19	19333-19338	brain	_	_
107-20	19339-19349	ROI‐to‐ROI	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
107-21	19350-19358	pairwise	_	_
107-22	19359-19367	matrices	_	_
107-23	19368-19369	(	_	_
107-24	19369-19372	see	_	_
107-25	19373-19386	Supplementary	_	_
107-26	19387-19390	Fig	_	_
107-27	19390-19391	.	_	_
107-28	19392-19393	1	_	_
107-29	19393-19394	)	_	_
107-30	19394-19395	.	_	_

108-1	19396-19400	Each	_	_
108-2	19401-19407	matrix	_	_
108-3	19408-19411	was	_	_
108-4	19412-19416	made	_	_
108-5	19417-19419	up	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
108-6	19420-19422	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
108-7	19423-19427	5995	_	_
108-8	19428-19429	(	_	_
108-9	19429-19430	=	_	_
108-10	19430-19431	N	_	_
108-11	19431-19432	*	_	_
108-12	19432-19433	(	_	_
108-13	19433-19434	N	_	_
108-14	19434-19435	 	_	_
108-15	19435-19436	−	_	_
108-16	19436-19437	 	_	_
108-17	19437-19438	1	_	_
108-18	19438-19439	)	_	_
108-19	19439-19440	/	_	_
108-20	19440-19441	2	_	_
108-21	19441-19442	,	_	_
108-22	19443-19447	with	_	_
108-23	19448-19449	N	_	_
108-24	19449-19450	 	_	_
108-25	19450-19451	=	_	_
108-26	19451-19452	 	_	_
108-27	19452-19455	110	_	_
108-28	19456-19461	nodes	_	_
108-29	19461-19462	)	_	_
108-30	19463-19471	pairwise	_	_
108-31	19472-19483	connections	_	_
108-32	19484-19485	(	_	_
108-33	19485-19490	edges	_	_
108-34	19490-19491	)	_	_
108-35	19491-19492	.	_	_

109-1	19493-19498	These	_	_
109-2	19499-19507	matrices	_	_
109-3	19508-19512	were	_	_
109-4	19513-19522	generated	_	_
109-5	19523-19525	in	_	_
109-6	19526-19532	MATLAB	_	_
109-7	19533-19534	(	_	_
109-8	19534-19537	The	_	_
109-9	19538-19547	MathWorks	_	_
109-10	19547-19548	,	_	_
109-11	19549-19552	Inc	_	_
109-12	19552-19553	.	_	_
109-13	19553-19554	,	_	_
109-14	19555-19561	Natick	_	_
109-15	19561-19562	,	_	_
109-16	19563-19576	Massachusetts	_	_
109-17	19576-19577	,	_	_
109-18	19578-19584	United	_	_
109-19	19585-19591	States	_	_
109-20	19591-19592	)	_	_
109-21	19593-19596	and	_	_
109-22	19597-19601	used	_	_
109-23	19602-19604	to	_	_
109-24	19605-19612	compare	_	_
109-25	19613-19620	network	_	_
109-26	19621-19633	connectivity	_	_
109-27	19634-19641	between	_	_
109-28	19642-19645	the	_	_
109-29	19646-19649	CON	_	_
109-30	19650-19653	and	_	_
109-31	19654-19657	ADD	_	_
109-32	19658-19664	groups	_	_
109-33	19665-19666	(	_	_
109-34	19666-19669	see	_	_
109-35	19670-19675	below	_	_
109-36	19675-19676	)	_	_
109-37	19676-19677	.	_	_

110-1	19678-19683	Graph	_	_
110-2	19684-19692	measures	_	_
110-3	19693-19699	Global	_	_
110-4	19700-19701	(	_	_
110-5	19701-19715	characteristic	_	_
110-6	19716-19720	path	_	_
110-7	19721-19727	length	_	_
110-8	19728-19731	and	_	_
110-9	19732-19742	clustering	_	_
110-10	19743-19754	coefficient	_	_
110-11	19754-19755	)	_	_
110-12	19756-19761	graph	_	_
110-13	19762-19770	measures	_	_
110-14	19771-19775	were	_	_
110-15	19776-19785	estimated	_	_
110-16	19786-19790	from	_	_
110-17	19791-19795	each	_	_
110-18	19796-19807	correlation	_	_
110-19	19808-19814	matrix	_	_
110-20	19815-19820	using	_	_
110-21	19821-19824	the	_	_
110-22	19825-19833	GraphVar	_	_
110-23	19834-19835	(	_	_
110-24	19835-19848	www.rfmri.org	_	_
110-25	19848-19849	/	_	_
110-26	19849-19857	GraphVar	_	_
110-27	19857-19858	)	_	_
110-28	19859-19866	toolbox	_	_
110-29	19867-19870	for	_	_
110-30	19871-19881	functional	_	_
110-31	19882-19887	brain	_	_
110-32	19888-19900	connectivity	_	_
110-33	19901-19903	in	_	_
110-34	19904-19910	MATLAB	_	_
110-35	19911-19912	(	_	_
110-36	19912-19915	The	_	_
110-37	19916-19925	MathWorks	_	_
110-38	19925-19926	,	_	_
110-39	19927-19930	Inc	_	_
110-40	19930-19931	.	_	_
110-41	19931-19932	,	_	_
110-42	19933-19939	Natick	_	_
110-43	19939-19940	,	_	_
110-44	19941-19954	Massachusetts	_	_
110-45	19954-19955	,	_	_
110-46	19956-19962	United	_	_
110-47	19963-19969	States	_	_
110-48	19969-19970	)	_	_
110-49	19970-19971	.	_	_

111-1	19972-19976	More	_	_
111-2	19977-19985	detailed	_	_
111-3	19986-19998	descriptions	_	_
111-4	19999-20001	of	_	_
111-5	20002-20007	brain	_	_
111-6	20008-20015	network	_	_
111-7	20016-20021	graph	_	_
111-8	20022-20030	measures	_	_
111-9	20031-20034	can	_	_
111-10	20035-20037	be	_	_
111-11	20038-20043	found	_	_
111-12	20044-20053	elsewhere	_	_
111-13	20053-20054	,	_	_
111-14	20055-20058	but	_	_
111-15	20059-20061	we	_	_
111-16	20062-20066	will	_	_
111-17	20067-20074	briefly	_	_
111-18	20075-20083	describe	_	_
111-19	20084-20089	these	_	_
111-20	20090-20097	metrics	_	_
111-21	20098-20102	here	_	_
111-22	20102-20103	.	_	_

112-1	20104-20118	Characteristic	_	_
112-2	20119-20123	path	_	_
112-3	20124-20130	length	_	_
112-4	20131-20133	is	_	_
112-5	20134-20137	the	_	_
112-6	20138-20145	minimum	_	_
112-7	20146-20152	number	_	_
112-8	20153-20155	of	_	_
112-9	20156-20161	edges	_	_
112-10	20162-20166	that	_	_
112-11	20167-20171	must	_	_
112-12	20172-20174	be	_	_
112-13	20175-20184	traversed	_	_
112-14	20185-20187	to	_	_
112-15	20188-20190	go	_	_
112-16	20191-20195	from	_	_
112-17	20196-20199	one	_	_
112-18	20200-20204	node	_	_
112-19	20205-20206	(	_	_
112-20	20206-20211	brain	_	_
112-21	20212-20218	region	_	_
112-22	20218-20219	)	_	_
112-23	20220-20222	to	_	_
112-24	20223-20230	another	_	_
112-25	20231-20233	in	_	_
112-26	20234-20235	a	_	_
112-27	20236-20243	network	_	_
112-28	20243-20244	.	_	_

113-1	20245-20248	For	_	_
113-2	20249-20250	a	_	_
113-3	20251-20255	pair	_	_
113-4	20256-20258	of	_	_
113-5	20259-20264	nodes	_	_
113-6	20265-20269	that	_	_
113-7	20270-20273	are	_	_
113-8	20274-20281	nearest	_	_
113-9	20282-20292	neighbours	_	_
113-10	20292-20293	,	_	_
113-11	20294-20297	the	_	_
113-12	20298-20302	path	_	_
113-13	20303-20309	length	_	_
113-14	20310-20312	is	_	_
113-15	20313-20314	1	_	_
113-16	20314-20315	.	_	_

114-1	20316-20319	The	_	_
114-2	20320-20330	clustering	_	_
114-3	20331-20342	coefficient	_	_
114-4	20342-20343	,	_	_
114-5	20344-20346	by	_	_
114-6	20347-20355	contrast	_	_
114-7	20355-20356	,	_	_
114-8	20357-20367	quantifies	_	_
114-9	20368-20371	the	_	_
114-10	20372-20379	density	_	_
114-11	20380-20382	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
114-12	20383-20394	connections	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
114-13	20395-20402	between	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
114-14	20403-20406	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
114-15	20407-20414	nearest	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
114-16	20415-20424	neighbour	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
114-17	20425-20427	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
114-18	20428-20429	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
114-19	20430-20434	node	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
114-20	20434-20435	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
114-21	20436-20439	and	_	_
114-22	20440-20449	describes	_	_
114-23	20450-20453	how	_	_
114-24	20454-20464	segregated	_	_
114-25	20465-20468	the	_	_
114-26	20469-20476	network	_	_
114-27	20477-20479	is	_	_
114-28	20479-20480	.	_	_

115-1	20481-20484	The	_	_
115-2	20485-20489	path	_	_
115-3	20490-20493	and	_	_
115-4	20494-20504	clustering	_	_
115-5	20505-20513	measures	_	_
115-6	20514-20517	are	_	_
115-7	20518-20523	first	_	_
115-8	20524-20533	estimated	_	_
115-9	20534-20536	at	_	_
115-10	20537-20541	each	_	_
115-11	20542-20546	node	_	_
115-12	20547-20549	of	_	_
115-13	20550-20553	the	_	_
115-14	20554-20564	connectome	_	_
115-15	20565-20571	before	_	_
115-16	20572-20574	an	_	_
115-17	20575-20582	average	_	_
115-18	20583-20584	(	_	_
115-19	20584-20590	global	_	_
115-20	20591-20596	value	_	_
115-21	20596-20597	)	_	_
115-22	20598-20600	is	_	_
115-23	20601-20609	computed	_	_
115-24	20610-20613	for	_	_
115-25	20614-20617	the	_	_
115-26	20618-20624	entire	_	_
115-27	20625-20635	connectome	_	_
115-28	20636-20639	for	_	_
115-29	20640-20644	each	_	_
115-30	20645-20656	participant	_	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
115-31	20656-20657	’	_	_
115-32	20657-20658	s	_	_
115-33	20659-20670	correlation	_	_
115-34	20671-20677	matrix	_	_
115-35	20677-20678	.	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	_

116-1	20679-20684	Graph	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	_
116-2	20685-20693	measures	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	http://maven.renci.org/NeuroBridge/neurobridge#2Level
116-3	20694-20697	for	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	http://maven.renci.org/NeuroBridge/neurobridge#2Level
116-4	20698-20702	each	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	http://maven.renci.org/NeuroBridge/neurobridge#2Level
116-5	20703-20714	participant	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	_
116-6	20715-20719	were	_	_
116-7	20720-20724	then	_	_
116-8	20725-20734	estimated	_	_
116-9	20735-20737	by	_	_
116-10	20738-20750	thresholding	_	_
116-11	20751-20755	each	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
116-12	20756-20762	matrix	_	_
116-13	20763-20765	at	_	_
116-14	20766-20767	a	_	_
116-15	20768-20777	selection	_	_
116-16	20778-20780	of	_	_
116-17	20781-20793	proportional	_	_
116-18	20794-20798	cost	_	_
116-19	20799-20800	(	_	_
116-20	20800-20801	K	_	_
116-21	20801-20802	)	_	_
116-22	20803-20813	thresholds	_	_
116-23	20814-20815	–	_	_
116-24	20816-20819	i.e	_	_
116-25	20819-20820	.	_	_
116-26	20821-20831	thresholds	_	_
116-27	20832-20836	that	_	_
116-28	20837-20843	retain	_	_
116-29	20844-20848	only	_	_
116-30	20849-20850	a	_	_
116-31	20851-20861	percentage	_	_
116-32	20862-20864	of	_	_
116-33	20865-20868	the	_	_
116-34	20869-20878	strongest	_	_
116-35	20879-20890	connections	_	_
116-36	20891-20892	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#Asperger'sDisorder
116-37	20892-20897	edges	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	_
116-38	20897-20898	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	_
116-39	20899-20901	in	_	_
116-40	20902-20905	the	_	_
116-41	20906-20913	network	_	_
116-42	20913-20914	.	_	_

117-1	20915-20925	Biological	_	_
117-2	20926-20934	networks	_	_
117-3	20935-20938	are	_	_
117-4	20939-20950	represented	_	_
117-5	20951-20953	by	_	_
117-6	20954-20960	sparse	_	_
117-7	20961-20972	connections	_	_
117-8	20972-20973	,	_	_
117-9	20974-20981	however	_	_
117-10	20981-20982	,	_	_
117-11	20983-20986	and	_	_
117-12	20987-20999	thresholding	_	_
117-13	21000-21002	is	_	_
117-14	21003-21004	a	_	_
117-15	21005-21014	necessary	_	_
117-16	21015-21019	step	_	_
117-17	21020-21022	to	_	_
117-18	21023-21030	extract	_	_
117-19	21031-21034	the	_	_
117-20	21035-21046	appropriate	_	_
117-21	21047-21058	topological	_	_
117-22	21059-21069	properties	_	_
117-23	21070-21072	of	_	_
117-24	21073-21081	networks	_	_
117-25	21081-21082	.	_	_

118-1	21083-21090	Because	_	_
118-2	21091-21096	graph	_	_
118-3	21097-21105	measures	_	_
118-4	21106-21109	can	_	_
118-5	21110-21114	also	_	_
118-6	21115-21117	be	_	_
118-7	21118-21127	sensitive	_	_
118-8	21128-21130	to	_	_
118-9	21131-21140	threshold	_	_
118-10	21141-21146	value	_	_
118-11	21146-21147	,	_	_
118-12	21148-21150	we	_	_
118-13	21151-21155	have	_	_
118-14	21156-21164	reported	_	_
118-15	21165-21168	our	_	_
118-16	21169-21177	measures	_	_
118-17	21178-21184	across	_	_
118-18	21185-21186	a	_	_
118-19	21187-21192	range	_	_
118-20	21193-21195	of	_	_
118-21	21196-21197	K	_	_
118-22	21198-21208	thresholds	_	_
118-23	21209-21210	(	_	_
118-24	21210-21211	1	_	_
118-25	21211-21212	 	_	_
118-26	21212-21213	⩽	_	_
118-27	21213-21214	 	_	_
118-28	21214-21215	K	_	_
118-29	21215-21216	 	_	_
118-30	21216-21217	⩽	_	_
118-31	21217-21218	 	_	_
118-32	21218-21219	5	_	_
118-33	21219-21220	,	_	_
118-34	21221-21231	increments	_	_
118-35	21232-21234	of	_	_
118-36	21235-21236	1	_	_
118-37	21236-21237	)	_	_
118-38	21237-21238	.	_	_

119-1	21239-21243	Here	_	_
119-2	21244-21245	K	_	_
119-3	21246-21256	represents	_	_
119-4	21257-21260	the	_	_
119-5	21261-21271	percentage	_	_
119-6	21272-21273	(	_	_
119-7	21273-21276	e.g	_	_
119-8	21276-21277	.	_	_
119-9	21277-21278	,	_	_
119-10	21279-21280	1	_	_
119-11	21280-21281	 	_	_
119-12	21281-21282	=	_	_
119-13	21282-21283	 	_	_
119-14	21283-21286	10%	_	_
119-15	21286-21287	)	_	_
119-16	21288-21294	number	_	_
119-17	21295-21297	of	_	_
119-18	21298-21303	edges	_	_
119-19	21304-21306	in	_	_
119-20	21307-21311	each	_	_
119-21	21312-21318	matrix	_	_
119-22	21319-21323	that	_	_
119-23	21324-21327	are	_	_
119-24	21328-21338	maintained	_	_
119-25	21339-21348	following	_	_
119-26	21349-21361	thresholding	_	_
119-27	21361-21362	.	_	_

120-1	21363-21365	We	_	_
120-2	21366-21374	employed	_	_
120-3	21375-21376	a	_	_
120-4	21377-21382	range	_	_
120-5	21383-21385	of	_	_
120-6	21386-21396	thresholds	_	_
120-7	21397-21399	to	_	_
120-8	21400-21409	represent	_	_
120-9	21410-21413	the	_	_
120-10	21414-21419	lower	_	_
120-11	21420-21423	and	_	_
120-12	21424-21429	upper	_	_
120-13	21430-21435	bound	_	_
120-14	21436-21438	of	_	_
120-15	21439-21440	a	_	_
120-16	21441-21452	small-world	_	_
120-17	21453-21459	system	_	_
120-18	21459-21460	,	_	_
120-19	21461-21464	and	_	_
120-20	21465-21469	that	_	_
120-21	21470-21478	preserve	_	_
120-22	21479-21483	only	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
120-23	21484-21487	the	_	_
120-24	21488-21497	strongest	_	_
120-25	21498-21508	functional	_	_
120-26	21509-21520	connections	_	_
120-27	21521-21524	for	_	_
120-28	21525-21534	efficient	_	_
120-29	21535-21543	parallel	_	_
120-30	21544-21555	information	_	_
120-31	21556-21566	processing	_	_
120-32	21567-21569	at	_	_
120-33	21570-21571	a	_	_
120-34	21572-21582	relatively	_	_
120-35	21583-21586	low	_	_
120-36	21587-21593	wiring	_	_
120-37	21594-21598	cost	_	_
120-38	21598-21599	.	_	_

121-1	21600-21603	All	_	_
121-2	21604-21609	graph	_	_
121-3	21610-21618	measures	_	_
121-4	21619-21623	were	_	_
121-5	21624-21632	computed	_	_
121-6	21633-21637	from	_	_
121-7	21638-21646	matrices	_	_
121-8	21647-21649	in	_	_
121-9	21650-21655	their	_	_
121-10	21656-21664	weighted	_	_
121-11	21665-21669	form	_	_
121-12	21670-21679	following	_	_
121-13	21680-21684	this	_	_
121-14	21685-21697	thresholding	_	_
121-15	21698-21707	procedure	_	_
121-16	21707-21708	.	_	_

122-1	21709-21719	Functional	_	_
122-2	21720-21732	connectivity	_	_
122-3	21733-21738	Group	_	_
122-4	21739-21750	comparisons	_	_
122-5	21751-21753	in	_	_
122-6	21754-21764	ROI‐to‐ROI	_	_
122-7	21765-21777	connectivity	_	_
122-8	21778-21784	across	_	_
122-9	21785-21793	matrices	_	_
122-10	21794-21798	were	_	_
122-11	21799-21807	assessed	_	_
122-12	21808-21813	using	_	_
122-13	21814-21817	the	_	_
122-14	21818-21826	Networks	_	_
122-15	21827-21832	Based	_	_
122-16	21833-21843	Statistics	_	_
122-17	21844-21845	(	_	_
122-18	21845-21848	NBS	_	_
122-19	21848-21849	)	_	_
122-20	21850-21857	Toolbox	_	_
122-21	21858-21861	for	_	_
122-22	21862-21868	MATLAB	_	_
122-23	21869-21870	(	_	_
122-24	21870-21873	The	_	_
122-25	21874-21883	MathWorks	_	_
122-26	21883-21884	,	_	_
122-27	21885-21888	Inc	_	_
122-28	21888-21889	.	_	_
122-29	21889-21890	,	_	_
122-30	21891-21897	Natick	_	_
122-31	21897-21898	,	_	_
122-32	21899-21912	Massachusetts	_	_
122-33	21912-21913	,	_	_
122-34	21914-21920	United	_	_
122-35	21921-21927	States	_	_
122-36	21927-21928	)	_	_
122-37	21928-21929	.	_	_

123-1	21930-21941	Comparisons	_	_
123-2	21942-21949	between	_	_
123-3	21950-21953	the	_	_
123-4	21954-21957	CON	_	_
123-5	21958-21961	and	_	_
123-6	21962-21965	ADD	_	_
123-7	21966-21972	groups	_	_
123-8	21973-21977	were	_	_
123-9	21978-21987	conducted	_	_
123-10	21988-21990	to	_	_
123-11	21991-21999	identify	_	_
123-12	22000-22005	those	_	_
123-13	22006-22011	nodes	_	_
123-14	22012-22018	across	_	_
123-15	22019-22022	the	_	_
123-16	22023-22033	connectome	_	_
123-17	22034-22038	that	_	_
123-18	22039-22045	showed	_	_
123-19	22046-22057	differences	_	_
123-20	22058-22060	in	_	_
123-21	22061-22073	connectivity	_	_
123-22	22073-22074	.	_	_

124-1	22075-22086	Independent	_	_
124-2	22087-22093	groups	_	_
124-3	22094-22101	t-tests	_	_
124-4	22102-22106	were	_	_
124-5	22107-22112	first	_	_
124-6	22113-22122	performed	_	_
124-7	22123-22125	to	_	_
124-8	22126-22130	test	_	_
124-9	22131-22134	for	_	_
124-10	22135-22136	a	_	_
124-11	22137-22150	between-group	_	_
124-12	22151-22161	difference	_	_
124-13	22162-22164	in	_	_
124-14	22165-22168	the	_	_
124-15	22169-22180	correlation	_	_
124-16	22181-22193	coefficients	_	_
124-17	22194-22196	at	_	_
124-18	22197-22201	each	_	_
124-19	22202-22204	of	_	_
124-20	22205-22208	the	_	_
124-21	22209-22212	110	_	_
124-22	22212-22213	 	_	_
124-23	22213-22214	×	_	_
124-24	22214-22215	 	_	_
124-25	22215-22216	(	_	_
124-26	22216-22219	110	_	_
124-27	22219-22220	–	_	_
124-28	22220-22221	1	_	_
124-29	22221-22222	)	_	_
124-30	22222-22223	/	_	_
124-31	22223-22224	2	_	_
124-32	22224-22225	 	_	_
124-33	22225-22226	=	_	_
124-34	22226-22227	 	_	_
124-35	22227-22231	5995	_	_
124-36	22232-22240	regional	_	_
124-37	22241-22249	pairings	_	_
124-38	22249-22250	.	_	_

125-1	22251-22256	Graph	_	_
125-2	22257-22271	sub-components	_	_
125-3	22272-22276	were	_	_
125-4	22277-22287	identified	_	_
125-5	22288-22293	among	_	_
125-6	22294-22297	the	_	_
125-7	22298-22309	connections	_	_
125-8	22310-22315	using	_	_
125-9	22316-22317	a	_	_
125-10	22318-22329	t-statistic	_	_
125-11	22330-22339	threshold	_	_
125-12	22340-22341	t	_	_
125-13	22341-22342	 	_	_
125-14	22342-22343	>	_	_
125-15	22343-22344	 	_	_
125-16	22344-22347	3.1	_	_
125-17	22347-22348	.	_	_

126-1	22349-22353	From	_	_
126-2	22354-22358	here	_	_
126-3	22358-22359	,	_	_
126-4	22360-22361	a	_	_
126-5	22362-22373	family-wise	_	_
126-6	22374-22379	error	_	_
126-7	22380-22381	(	_	_
126-8	22381-22384	FWE	_	_
126-9	22384-22385	)	_	_
126-10	22386-22395	corrected	_	_
126-11	22396-22403	p-value	_	_
126-12	22404-22405	(	_	_
126-13	22405-22406	p	_	_
126-14	22406-22407	 	_	_
126-15	22407-22408	<	_	_
126-16	22408-22409	 	_	_
126-17	22409-22413	0.05	_	_
126-18	22413-22414	)	_	_
126-19	22415-22418	was	_	_
126-20	22419-22429	calculated	_	_
126-21	22430-22433	for	_	_
126-22	22434-22437	the	_	_
126-23	22438-22442	size	_	_
126-24	22443-22445	of	_	_
126-25	22446-22450	each	_	_
126-26	22451-22460	resulting	_	_
126-27	22461-22470	component	_	_
126-28	22471-22476	using	_	_
126-29	22477-22488	permutation	_	_
126-30	22489-22496	testing	_	_
126-31	22497-22498	(	_	_
126-32	22498-22502	5000	_	_
126-33	22503-22515	permutations	_	_
126-34	22515-22516	)	_	_
126-35	22516-22517	.	_	_

127-1	22518-22521	Two	_	_
127-2	22522-22523	(	_	_
127-3	22523-22526	CON	_	_
127-4	22526-22527	 	_	_
127-5	22527-22528	>	_	_
127-6	22528-22529	 	_	_
127-7	22529-22532	ADD	_	_
127-8	22533-22536	and	_	_
127-9	22537-22540	ADD	_	_
127-10	22540-22541	 	_	_
127-11	22541-22542	>	_	_
127-12	22542-22543	 	_	_
127-13	22543-22546	CON	_	_
127-14	22546-22547	)	_	_
127-15	22548-22556	analyses	_	_
127-16	22557-22561	were	_	_
127-17	22562-22571	conducted	_	_
127-18	22572-22585	independently	_	_
127-19	22586-22588	on	_	_
127-20	22589-22592	the	_	_
127-21	22593-22597	gain	_	_
127-22	22598-22610	anticipation	_	_
127-23	22610-22611	 	_	_
127-24	22611-22612	>	_	_
127-25	22612-22613	 	_	_
127-26	22613-22620	neutral	_	_
127-27	22621-22633	anticipation	_	_
127-28	22634-22642	contrast	_	_
127-29	22643-22651	matrices	_	_
127-30	22651-22652	.	_	_

128-1	22653-22658	Given	_	_
128-2	22659-22662	the	_	_
128-3	22663-22674	differences	_	_
128-4	22675-22677	in	_	_
128-5	22678-22686	scanners	_	_
128-6	22687-22693	across	_	_
128-7	22694-22697	the	_	_
128-8	22698-22703	three	_	_
128-9	22704-22709	sites	_	_
128-10	22709-22710	,	_	_
128-11	22711-22716	these	_	_
128-12	22717-22720	NBS	_	_
128-13	22721-22729	analyses	_	_
128-14	22730-22734	were	_	_
128-15	22735-22744	conducted	_	_
128-16	22745-22750	while	_	_
128-17	22751-22762	controlling	_	_
128-18	22763-22766	for	_	_
128-19	22767-22772	study	_	_
128-20	22773-22777	site	_	_
128-21	22777-22778	.	_	_

129-1	22779-22782	NBS	_	_
129-2	22783-22786	has	_	_
129-3	22787-22797	previously	_	_
129-4	22798-22802	been	_	_
129-5	22803-22807	used	_	_
129-6	22808-22810	to	_	_
129-7	22811-22819	identify	_	_
129-8	22820-22828	specific	_	_
129-9	22829-22837	networks	_	_
129-10	22838-22840	of	_	_
129-11	22841-22846	nodes	_	_
129-12	22847-22853	across	_	_
129-13	22854-22855	a	_	_
129-14	22856-22866	connectome	_	_
129-15	22867-22871	that	_	_
129-16	22872-22878	differ	_	_
129-17	22879-22886	between	_	_
129-18	22887-22895	clinical	_	_
129-19	22896-22907	populations	_	_
129-20	22908-22914	during	_	_
129-21	22915-22924	different	_	_
129-22	22925-22938	psychological	_	_
129-23	22939-22948	processes	_	_
129-24	22948-22949	.	_	_

130-1	22950-22957	Network	_	_
130-2	22958-22971	visualisation	_	_
130-3	22972-22980	Networks	_	_
130-4	22981-22985	that	_	_
130-5	22986-22993	emerged	_	_
130-6	22994-22998	from	_	_
130-7	22999-23004	group	_	_
130-8	23005-23016	comparisons	_	_
130-9	23017-23019	in	_	_
130-10	23020-23023	NBS	_	_
130-11	23024-23028	were	_	_
130-12	23029-23039	visualised	_	_
130-13	23040-23043	and	_	_
130-14	23044-23053	presented	_	_
130-15	23054-23059	using	_	_
130-16	23060-23065	brain	_	_
130-17	23066-23078	connectivity	_	_
130-18	23079-23083	maps	_	_
130-19	23084-23087	and	_	_
130-20	23088-23096	circular	_	_
130-21	23097-23110	connectograms	_	_
130-22	23111-23116	using	_	_
130-23	23117-23120	the	_	_
130-24	23121-23131	NeuroMArVL	_	_
130-25	23132-23140	software	_	_
130-26	23141-23142	(	_	_
130-27	23142-23173	www.immersive.erc.monash.edu.au	_	_
130-28	23173-23174	/	_	_
130-29	23174-23184	neuromarvl	_	_
130-30	23184-23185	)	_	_
130-31	23185-23186	.	_	_
































































































































